CINXE.COM
Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under | Infectious Diseases of Poverty | Full Text
<!DOCTYPE html> <html lang="en" class="no-js"> <head> <meta charset="UTF-8"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta name="applicable-device" content="pc,mobile"> <meta name="viewport" content="width=device-width, initial-scale=1"> <title>Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under | Infectious Diseases of Poverty | Full Text</title> <meta name="citation_abstract" content="Artemisinin-based combination therapies are recommended as first-line treatments for uncomplicated falciparum malaria, but there is little evaluation of their efficacy and effects on uncomplicated malaria-associated anaemia in children aged 2 years and under. Parasitological efficacy and effects on malaria-associated anaemia were evaluated in 250 malarious children aged 2 years and under, and efficacy was evaluated in 603 malarious children older than two but younger than 5 years of age following treatment with artesunate-amodiaquine (AA) or artemether-lumefantrine (AL). Kinetics of the disposition of parasitaemia following treatment were evaluated using a non-compartment model. Late-appearing anaemia (LAA) was diagnosed using the following criteria: clearance of parasitaemia, fever and other symptoms occurring within 7 days of starting treatment, adequate clinical and parasitological response on days 28–42, haematocrit (HCT) ≥ 30 % at 1 and/or 2 weeks, a fall in HCT to < 30 % occurring at 3–6 weeks, absence of concomitant illness at 1–6 weeks, and absence of asexual parasitaemia detected using both microscopy and polymerase chain reaction (PCR) at 1–6 weeks. Overall, in children aged 2 years and under, the PCR-corrected parasitological efficacy was 97.2 % (95 % CI 92.8–101.6), which was similar for both treatments. In children older than 2 years, parasitological efficacy was also similar for both treatments, but parasite prevalence 1 day after treatment began was significantly higher, and fever and parasite clearance times were significantly faster in the AA-treated children compared with the AL-treated children. Declines in parasitaemia were monoexponential with an estimated elimination half-time of 1 h. Elimination half-times were similar for both treatments. In children aged 2 years and under who were anaemic at presentation, the mean anaemia recovery time was 12.1 days (95 % CI 10.6–13.6, n = 127), which was similar for both treatments. Relatively asymptomatic LAA occurred in 11 children (4.4 %) aged 2 years and under, the recovery from which was uneventful. This study showed that AA and AL are efficacious treatments for uncomplicated falciparum malaria in Nigerian children aged 2 years and under, and that AA clears parasitaemia and fever significantly faster than AL in children older than 2 years. Both treatments may cause a relatively asymptomatic LAA with uneventful recovery in a small proportion of children aged 2 years and under. Pan African Clinical Trial Registry PACTR201508001188143, 3 July 2015; PACTR201510001189370, 3 July 2015; PACTR201508001191898, 7 July 2015 and PACTR201508001193368, 8 July 2015  http://www.pactr.org ."/> <meta name="journal_id" content="40249"/> <meta name="dc.title" content="Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under"/> <meta name="dc.source" content="Infectious Diseases of Poverty 2016 5:1"/> <meta name="dc.format" content="text/html"/> <meta name="dc.publisher" content="BioMed Central"/> <meta name="dc.date" content="2016-07-06"/> <meta name="dc.type" content="OriginalPaper"/> <meta name="dc.language" content="En"/> <meta name="dc.copyright" content="2016 The Author(s)."/> <meta name="dc.rights" content="2016 The Author(s)."/> <meta name="dc.rightsAgent" content="reprints@biomedcentral.com"/> <meta name="dc.description" content="Artemisinin-based combination therapies are recommended as first-line treatments for uncomplicated falciparum malaria, but there is little evaluation of their efficacy and effects on uncomplicated malaria-associated anaemia in children aged 2&nbsp;years and under. Parasitological efficacy and effects on malaria-associated anaemia were evaluated in 250 malarious children aged 2&nbsp;years and under, and efficacy was evaluated in 603 malarious children older than two but younger than 5&nbsp;years of age following treatment with artesunate-amodiaquine (AA) or artemether-lumefantrine (AL). Kinetics of the disposition of parasitaemia following treatment were evaluated using a non-compartment model. Late-appearing anaemia (LAA) was diagnosed using the following criteria: clearance of parasitaemia, fever and other symptoms occurring within 7&nbsp;days of starting treatment, adequate clinical and parasitological response on days 28–42, haematocrit (HCT) ≥ 30&nbsp;% at 1 and/or 2&nbsp;weeks, a fall in HCT to &lt; 30&nbsp;% occurring at 3–6 weeks, absence of concomitant illness at 1–6 weeks, and absence of asexual parasitaemia detected using both microscopy and polymerase chain reaction (PCR) at 1–6 weeks. Overall, in children aged 2&nbsp;years and under, the PCR-corrected parasitological efficacy was 97.2&nbsp;% (95&nbsp;% CI 92.8–101.6), which was similar for both treatments. In children older than 2&nbsp;years, parasitological efficacy was also similar for both treatments, but parasite prevalence 1&nbsp;day after treatment began was significantly higher, and fever and parasite clearance times were significantly faster in the AA-treated children compared with the AL-treated children. Declines in parasitaemia were monoexponential with an estimated elimination half-time of 1&nbsp;h. Elimination half-times were similar for both treatments. In children aged 2&nbsp;years and under who were anaemic at presentation, the mean anaemia recovery time was 12.1&nbsp;days (95&nbsp;% CI 10.6–13.6, n = 127), which was similar for both treatments. Relatively asymptomatic LAA occurred in 11 children (4.4&nbsp;%) aged 2&nbsp;years and under, the recovery from which was uneventful. This study showed that AA and AL are efficacious treatments for uncomplicated falciparum malaria in Nigerian children aged 2&nbsp;years and under, and that AA clears parasitaemia and fever significantly faster than AL in children older than 2&nbsp;years. Both treatments may cause a relatively asymptomatic LAA with uneventful recovery in a small proportion of children aged 2&nbsp;years and under. Pan African Clinical Trial Registry PACTR201508001188143, 3 July 2015; PACTR201510001189370, 3 July 2015; PACTR201508001191898, 7 July 2015 and PACTR201508001193368, 8 July 2015&nbsp; http://www.pactr.org ."/> <meta name="prism.issn" content="2049-9957"/> <meta name="prism.publicationName" content="Infectious Diseases of Poverty"/> <meta name="prism.publicationDate" content="2016-07-06"/> <meta name="prism.volume" content="5"/> <meta name="prism.number" content="1"/> <meta name="prism.section" content="OriginalPaper"/> <meta name="prism.startingPage" content="1"/> <meta name="prism.endingPage" content="14"/> <meta name="prism.copyright" content="2016 The Author(s)."/> <meta name="prism.rightsAgent" content="reprints@biomedcentral.com"/> <meta name="prism.url" content="https://idpjournal.biomedcentral.com/articles/10.1186/s40249-016-0165-2"/> <meta name="prism.doi" content="doi:10.1186/s40249-016-0165-2"/> <meta name="citation_pdf_url" content="https://idpjournal.biomedcentral.com/counter/pdf/10.1186/s40249-016-0165-2"/> <meta name="citation_fulltext_html_url" content="https://idpjournal.biomedcentral.com/articles/10.1186/s40249-016-0165-2"/> <meta name="citation_journal_title" content="Infectious Diseases of Poverty"/> <meta name="citation_journal_abbrev" content="Infect Dis Poverty"/> <meta name="citation_publisher" content="BioMed Central"/> <meta name="citation_issn" content="2049-9957"/> <meta name="citation_title" content="Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under"/> <meta name="citation_volume" content="5"/> <meta name="citation_issue" content="1"/> <meta name="citation_publication_date" content="2016/12"/> <meta name="citation_online_date" content="2016/07/06"/> <meta name="citation_firstpage" content="1"/> <meta name="citation_lastpage" content="14"/> <meta name="citation_article_type" content="Research Article"/> <meta name="citation_fulltext_world_readable" content=""/> <meta name="citation_language" content="en"/> <meta name="dc.identifier" content="doi:10.1186/s40249-016-0165-2"/> <meta name="DOI" content="10.1186/s40249-016-0165-2"/> <meta name="size" content="312059"/> <meta name="citation_doi" content="10.1186/s40249-016-0165-2"/> <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1186/s40249-016-0165-2&api_key="/> <meta name="description" content="Artemisinin-based combination therapies are recommended as first-line treatments for uncomplicated falciparum malaria, but there is little evaluation of their efficacy and effects on uncomplicated malaria-associated anaemia in children aged 2&nbsp;years and under. Parasitological efficacy and effects on malaria-associated anaemia were evaluated in 250 malarious children aged 2&nbsp;years and under, and efficacy was evaluated in 603 malarious children older than two but younger than 5&nbsp;years of age following treatment with artesunate-amodiaquine (AA) or artemether-lumefantrine (AL). Kinetics of the disposition of parasitaemia following treatment were evaluated using a non-compartment model. Late-appearing anaemia (LAA) was diagnosed using the following criteria: clearance of parasitaemia, fever and other symptoms occurring within 7&nbsp;days of starting treatment, adequate clinical and parasitological response on days 28–42, haematocrit (HCT) ≥ 30&nbsp;% at 1 and/or 2&nbsp;weeks, a fall in HCT to &lt; 30&nbsp;% occurring at 3–6 weeks, absence of concomitant illness at 1–6 weeks, and absence of asexual parasitaemia detected using both microscopy and polymerase chain reaction (PCR) at 1–6 weeks. Overall, in children aged 2&nbsp;years and under, the PCR-corrected parasitological efficacy was 97.2&nbsp;% (95&nbsp;% CI 92.8–101.6), which was similar for both treatments. In children older than 2&nbsp;years, parasitological efficacy was also similar for both treatments, but parasite prevalence 1&nbsp;day after treatment began was significantly higher, and fever and parasite clearance times were significantly faster in the AA-treated children compared with the AL-treated children. Declines in parasitaemia were monoexponential with an estimated elimination half-time of 1&nbsp;h. Elimination half-times were similar for both treatments. In children aged 2&nbsp;years and under who were anaemic at presentation, the mean anaemia recovery time was 12.1&nbsp;days (95&nbsp;% CI 10.6–13.6, n = 127), which was similar for both treatments. Relatively asymptomatic LAA occurred in 11 children (4.4&nbsp;%) aged 2&nbsp;years and under, the recovery from which was uneventful. This study showed that AA and AL are efficacious treatments for uncomplicated falciparum malaria in Nigerian children aged 2&nbsp;years and under, and that AA clears parasitaemia and fever significantly faster than AL in children older than 2&nbsp;years. Both treatments may cause a relatively asymptomatic LAA with uneventful recovery in a small proportion of children aged 2&nbsp;years and under. Pan African Clinical Trial Registry PACTR201508001188143, 3 July 2015; PACTR201510001189370, 3 July 2015; PACTR201508001191898, 7 July 2015 and PACTR201508001193368, 8 July 2015&nbsp; http://www.pactr.org ."/> <meta name="dc.creator" content="Sowunmi, Akintunde"/> <meta name="dc.creator" content="Akano, Kazeem"/> <meta name="dc.creator" content="Ayede, Adejumoke I."/> <meta name="dc.creator" content="Ntadom, Godwin"/> <meta name="dc.creator" content="Adewoye, Elsie O."/> <meta name="dc.creator" content="Fatunmbi, Bayo"/> <meta name="dc.creator" content="Aderoyeje, Temitope"/> <meta name="dc.subject" content="Infectious Diseases"/> <meta name="dc.subject" content="Tropical Medicine"/> <meta name="dc.subject" content="Public Health"/> <meta name="citation_reference" content="citation_title=World malaria report 2014; citation_publication_date=2014; citation_id=CR1; citation_publisher=WHO"/> <meta name="citation_reference" content="Federal Ministry of Health. National Antimalaria Treatment Guideline. Abuja, Nigeria. Federal Ministry of Health; 2005."/> <meta name="citation_reference" content="citation_title=Status Report on Artemisinin and ACT Resistance; citation_publication_date=2015; citation_id=CR3; citation_publisher=WHO"/> <meta name="citation_reference" content="citation_journal_title=Emerg Infect Dis; citation_title=Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border; citation_author=C Wongsrichanalai, S Meshnick; citation_volume=14; citation_publication_date=2008; citation_pages=716-719; citation_doi=10.3201/eid1405.071601; citation_id=CR4"/> <meta name="citation_reference" content="citation_journal_title=N Engl J Med; citation_title=Evidence of artemisinin resistance in western Cambodia; citation_author=H Noedl, Y Se, K Schaecher, BL Smith, D Socheat, MM Fukuda; citation_volume=359; citation_publication_date=2008; citation_pages=2619-2620; citation_doi=10.1056/NEJMc0805011; citation_id=CR5"/> <meta name="citation_reference" content="citation_journal_title=Clin Infect Dis; citation_title=Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia; citation_author=H Noedl, Y Se, S Sriwichai, K Schaecher, P Teja-Isavadharm, B Smith, W Rutvisuttinunt, D Bethell, S Surasri, MM Fukuda, D Socheat, TL Cham; citation_volume=51; citation_publication_date=2010; citation_pages=e82-e89; citation_doi=10.1086/657120; citation_id=CR6"/> <meta name="citation_reference" content="citation_journal_title=PLoS One; citation_title=Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment; citation_author=VI Carrara, J Zwang, EA Ashley, RN Price, K Stepniewka, B Marion, A Brockman, T Anderson, R McGready, L Phaiphun, P Stephane, M Vugt, R Hutagalung, KM Lwin, AP Phyo, P Piyanuch, M Imwong, S Pukrittayakamee, P Singhasivanon, NJ White, F Nosten; citation_volume=4; citation_publication_date=2009; citation_pages=e511; citation_doi=10.1371/journal.pone.0004551; citation_id=CR7"/> <meta name="citation_reference" content="citation_journal_title=Malar J; citation_title= Pfmdr1 copy number and artemisinin derivatives combination therapy failure in falciparum malaria in Cambodia; citation_author=P Lim, A Alker, N Khim, N Shah, S Incardona, S Doung, P Yi, D Bouth, C Boucher, P Mercereau, S Meshnick, C Wongsrichanalai, T Fandeur, J Bras, P Ringwald, F Ariey; citation_volume=8; citation_publication_date=2009; citation_pages=11; citation_doi=10.1186/1475-2875-8-11; citation_id=CR8"/> <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study; citation_author=AP Phyo, S Nkhoma, K Stepniewska, EA Ashley, S Nair, R McGready, C Moo, S Al-Saai, AM Dondorp, KM Lwin, P Singhasivanon, N Day, NJ White, TMJ Anderson, F Nosten; citation_volume=379; citation_publication_date=2012; citation_pages=1960-1966; citation_doi=10.1016/S0140-6736(12)60484-X; citation_id=CR9"/> <meta name="citation_reference" content="citation_journal_title=PLoS ONE; citation_title=Decline responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast; citation_author=S Borrmann, P Sasi, L Mwai, M Bashraheil, A Abdallah, S Muriithi, H Frühauf, B Schaub, J Pfeil, J Peshu, W Hanpithakpong, A Rippert, E Juma, B Tsofa, M Mosobo, B Lowe, F Oseir, G Fegan, N Lindegårdh, A Nzila, N Peshu, M Mackinnon, K Marsh; citation_volume=6; citation_publication_date=2011; citation_pages=26005; citation_doi=10.1371/journal.pone.0026005; citation_id=CR10"/> <meta name="citation_reference" content="citation_journal_title=Mem Inst Oswaldo Cruz Rio de Janeiro; citation_title=Evidence of an increased incidence of day 3 parasitaemia in Suriname: an indicator of the emerging resistance of Plasmodium falciparum to artemether; citation_author=SGS Vreden, JK Jitan, RD Bansie, MA Adhin; citation_volume=108; citation_publication_date=2013; citation_pages=968-973; citation_doi=10.1590/0074-0276130167; citation_id=CR11"/> <meta name="citation_reference" content="citation_title=Chemotherapy of Malaria and Resistance to Antimalarials; citation_publication_date=1973; citation_id=CR12; citation_publisher=World Health Organization"/> <meta name="citation_reference" content="citation_journal_title=Ann Trop Med Parasitol; citation_title=Malaria in Nigeria: a revisit; citation_author=LA Salako, FO Ajayi, A Sowunmi, O Walker; citation_volume=84; citation_publication_date=1990; citation_pages=435-445; citation_id=CR13"/> <meta name="citation_reference" content="citation_journal_title=Am J Trop Med Hyg; citation_title=Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulphalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria; citation_author=A Sowunmi, GO Gbotosho, CT Happi, AA Adedeji, FA Fehintola; citation_volume=77; citation_publication_date=2007; citation_pages=235-241; citation_id=CR14"/> <meta name="citation_reference" content="citation_journal_title=Am J Therap; citation_title=Use of area under the curve to evaluate the effects of antimalarial drugs on malaria-associated anaemia after treatment; citation_author=A Sowunmi, GO Gbotosho, CT Happi, O Folarin, T Okuboyejo, O Michael, B Fatunmbi; citation_volume=118; citation_publication_date=2011; citation_pages=1190-1197; citation_id=CR15"/> <meta name="citation_reference" content="citation_journal_title=Mal Chemother Ctrl Elim; citation_title=Early changes in Plasmodium falciparum asexual and sexual populations in children with acute infections following treatment with artemisinin-based combination drugs; citation_author=A Sowunmi, TM Okuboyejo, GO Gbotosho, CT Happi; citation_volume=1; citation_publication_date=2012; citation_pages=235498; citation_id=CR16"/> <meta name="citation_reference" content="citation_journal_title=Am J Trop Med Hyg; citation_title=Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments; citation_author=GO Gbotosho, A Sowunmi, CT Happi, TM Okuboyejo; citation_volume=84; citation_publication_date=2011; citation_pages=936-943; citation_doi=10.4269/ajtmh.2011.10-0722; citation_id=CR17"/> <meta name="citation_reference" content="citation_journal_title=Am J Trop Med Hyg; citation_title=Therapeutic efficacy and effect of artemether-lumefantrine and artesunate-amodiaquine cofomulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in southwest Nigeria; citation_author=GO Gbotosho, A Sowunmi, TM Okuboyejo, CT Happi, OO Folarin, SO Michael, EO Adewoye; citation_volume=84; citation_publication_date=2011; citation_pages=813-819; citation_doi=10.4269/ajtmh.2011.10-0582; citation_id=CR18"/> <meta name="citation_reference" content="citation_journal_title=Malar J; citation_title=Early variations in Plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance; citation_author=OS Michael, GO Gbotosho, OA Folarin, T Okuboyejo, A Sowunmi, AMJ Oduola, CT Happi; citation_volume=9; citation_publication_date=2010; citation_pages=335; citation_doi=10.1186/1475-2875-9-335; citation_id=CR19"/> <meta name="citation_reference" content="citation_journal_title=Am J Trop Med Hyg; citation_title=Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five year-old Nigerian children; citation_author=S Oguche, HU Okafor, I Watila, M Meremikwu, P Agomo, W Ogala, C Agomo, G Ntadom, O Banjo, T Okuboyejo, G Ogunrinde, F Odey, O Aina, T Sofola, A Sowunmi; citation_volume=91; citation_publication_date=2014; citation_pages=925-935; citation_doi=10.4269/ajtmh.13-0248; citation_id=CR20"/> <meta name="citation_reference" content="citation_journal_title=Antimicrob Agent Chemother; citation_title=Assessment of the pharmacodynamics properties of antimalarial drugs in vivo ; citation_author=NJ White; citation_volume=41; citation_publication_date=1997; citation_pages=1413-1422; citation_id=CR21"/> <meta name="citation_reference" content="citation_journal_title=Clin Drug Investig; citation_title=Comparative Plasmodium falciparum kinetics during treatment with amodiaquine and chloroquine in children; citation_author=A Sowunmi, AG Falade, AA Adedeji, AI Ayede, BA Fateye, CO Sowunmi, AMJ Oduola; citation_volume=21; citation_publication_date=2001; citation_pages=371-381; citation_doi=10.2165/00044011-200121050-00007; citation_id=CR22"/> <meta name="citation_reference" content="citation_journal_title=Acta Tropic; citation_title=Effects of amodiaquine, artesunate, and artesunate-amodiaquine of Plasmodium falciparum malaria-associated anaemia in children; citation_author=A Sowunmi, ST Balogun, GO Gbotosho, CT Happi; citation_volume=109; citation_publication_date=2009; citation_pages=55-60; citation_doi=10.1016/j.actatropica.2008.09.022; citation_id=CR23"/> <meta name="citation_reference" content="citation_journal_title=BMC Infect Dis; citation_title=Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children; citation_author=A Sowunmi, K Akano, AI Ayede, G Ntadom, T Aderoyeje, EO Adewoye, B Fatunmbi; citation_volume=15; citation_publication_date=2015; citation_pages=454; citation_doi=10.1186/s12879-015-1219-y; citation_id=CR24"/> <meta name="citation_reference" content="citation_title=Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria; citation_publication_date=2003; citation_id=CR25; citation_publisher=World Health Organization"/> <meta name="citation_reference" content="citation_title=Methods for surveillance of antimalarial drug efficacy; citation_publication_date=2009; citation_id=CR26; citation_publisher=Geneva"/> <meta name="citation_reference" content="citation_title=Epi Info Version 6. A Word Processing Data Base and Statistics Program for Public Health on IBM-compatible Microcomputers; citation_publication_date=1994; citation_id=CR27; citation_publisher=Centers for Disease Control and Prevention"/> <meta name="citation_reference" content="citation_title=SPSS for Windows Release 20.0 (standard version); citation_publication_date=2011; citation_id=CR28; citation_publisher=SPSS Inc"/> <meta name="citation_reference" content="Schramm B, Valch P, Baudin C, Mazinda CS, Smith R, Pinoges I, Sundaygar T, Zolia YM, Jones JJ, Comte E, Bruneel A, Branger M, Jullien V, Cam G, Kiechel J-R, Ashley EA, Guérin PJ. Tolerability and safety of artesunate-amodiaquine and artemether-lumefatrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trial in Nimba County, Liberia. Malar J. 2013;12:250."/> <meta name="citation_reference" content="citation_journal_title=Emerg Infect Dis; citation_title=Intravenous artesunate for severe malaria in travelers, Europe; citation_author=T Zoller, T Junghanss, A Kapaun, I Gjørup, J Richter, M Hugo-Persson, K Mørch, B Foroutan, N Suttorp, S Yürek, H Flick; citation_volume=17; citation_publication_date=2011; citation_pages=771-777; citation_doi=10.3201/eid1705.101229; citation_id=CR30"/> <meta name="citation_reference" content="citation_journal_title=Malar J; citation_title=Treatment outcome of intravenous artesunate in patients with severe malaria in Netherlands and Belgium; citation_author=AR Kreeftmeijer-Vetger, PJ Genderen, LG Visser, WFW Bierman, J Clerinx, CKW Veldehuizen, PJ Vries; citation_volume=11; citation_publication_date=2012; citation_pages=102; citation_doi=10.1186/1475-2875-11-102; citation_id=CR31"/> <meta name="citation_reference" content="citation_title=WHO information note on delayed haemolytic anaemia following treatment with artesunate; citation_publication_date=2013; citation_id=CR32; citation_publisher=WHO"/> <meta name="citation_reference" content="citation_journal_title=J Infect Dis; citation_title=Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria – a double-center prospective study; citation_author=T Rolling, T Agbenyega, S Issifou, AA Adegnika, J Sylverken, D Spahlinger, D Ansong, SJ Löhr, GD Burchard, J May, B Mordmuller, S Krishna, PG Kremsner, JP Cramer; citation_volume=209; citation_publication_date=2014; citation_pages=1921-1928; citation_doi=10.1093/infdis/jit841; citation_id=CR33"/> <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins; citation_author=S Jauréguiberry, PA Ndour, C Roussel, F Ader, I Safeukui, M Nguyen, S Biligui, L Ciceron, O Mouri, E Kendjo, M Vray, A Angoulvant, J Mayaux, K Haldar, D Mazier, M Danis, E Caumes, M Thellier, P Buffet; citation_volume=124; citation_publication_date=2014; citation_pages=167-175; citation_doi=10.1182/blood-2014-02-555953; citation_id=CR34"/> <meta name="citation_author" content="Sowunmi, Akintunde"/> <meta name="citation_author_institution" content="Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria"/> <meta name="citation_author_institution" content="Institute for Medical Research and Training, University of Ibadan, Ibadan, Nigeria"/> <meta name="citation_author" content="Akano, Kazeem"/> <meta name="citation_author_institution" content="Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria"/> <meta name="citation_author" content="Ayede, Adejumoke I."/> <meta name="citation_author_institution" content="Department of Paediatrics, University of Ibadan, Ibadan, Nigeria"/> <meta name="citation_author" content="Ntadom, Godwin"/> <meta name="citation_author_institution" content="Malaria Elimination Programme, Federal Ministry of Health, Abuja, Nigeria"/> <meta name="citation_author" content="Adewoye, Elsie O."/> <meta name="citation_author_institution" content="Department of Physiology, University of Ibadan, Ibadan, Nigeria"/> <meta name="citation_author" content="Fatunmbi, Bayo"/> <meta name="citation_author_institution" content="World Health Organization, Regional Office for the Western Pacific, Phnom Penh, Cambodia"/> <meta name="citation_author" content="Aderoyeje, Temitope"/> <meta name="citation_author_institution" content="Department of Clinical Pharmacology, University College Hospital, Ibadan, Nigeria"/> <meta name="format-detection" content="telephone=no"> <link rel="apple-touch-icon" sizes="180x180" href=/static/img/favicons/bmc/apple-touch-icon-582ef1d0f5.png> <link rel="icon" type="image/png" sizes="192x192" href=/static/img/favicons/bmc/android-chrome-192x192-9625b7cdba.png> <link rel="icon" type="image/png" sizes="32x32" href=/static/img/favicons/bmc/favicon-32x32-5d7879efe1.png> <link rel="icon" type="image/png" sizes="16x16" href=/static/img/favicons/bmc/favicon-16x16-c241ac1a2f.png> <link rel="shortcut icon" data-test="shortcut-icon" href=/static/img/favicons/bmc/favicon-1886637b78.ico> <link rel="manifest" href=/static/app-bmc/manifest-3bb9ad383b.json> <meta name="msapplication-config" content=/static/app-bmc/browserconfig-ecd9aa8205.xml> <meta name="msapplication-TileColor" content="#1b3051"> <meta name="msapplication-TileImage" content=/static/img/favicons/bmc/app-icon-144x144.png> <meta name="theme-color" content="#1b3051"> <script>(function(H){H.className=H.className.replace(/\bno-js\b/,'js')})(document.documentElement)</script> <link rel="stylesheet" media="screen" href=/static/app-bmc/css/core-article-f3872e738d.css> <link rel="stylesheet" media="screen" href=/static/app-bmc/css/core-eac3097aa4.css> <link rel="stylesheet" media="print" href=/static/app-bmc/css/print-b8af42253b.css> <!-- This template is only used by BMC for now --> <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) { button{line-height:inherit}html,label{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}html{-webkit-font-smoothing:subpixel-antialiased;box-sizing:border-box;color:#333;font-size:100%;height:100%;line-height:1.61803;overflow-y:scroll}*{box-sizing:inherit}body{background:#fff;margin:0;max-width:100%;min-height:100%}button,div,form,input,p{margin:0;padding:0}body{padding:0}a{color:#004b83;text-decoration:underline;text-decoration-skip-ink:auto}a>img{vertical-align:middle}h1,h2{color:#1b3051;font-style:normal;font-weight:700}h1{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:28px;line-height:1.4}html.webfonts-loaded h1,html.webfonts-loaded h2,html.webfonts-loaded h3{font-family:Europa,Trebuchet MS}h2{font-size:26px;margin-bottom:.5em}h2,h3{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;line-height:1.4}h3{color:#1b3051;font-size:18px;font-style:normal;margin-bottom:.7em}.c-navbar{background:#f2f2f2;border-bottom:1px solid #d9d9d9;border-top:1px solid #d9d9d9;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:14px;line-height:1.61803;padding:16px 0}.c-navbar--with-submit-button{padding-bottom:24px}@media only screen and (min-width:540px){.c-navbar--with-submit-button{padding-bottom:16px}}.c-navbar__container{display:flex;flex-wrap:wrap;justify-content:space-between;margin:0 auto;max-width:1280px;padding:0 16px}.c-navbar__content{display:flex;flex:0 1 auto}.c-navbar__nav{align-items:center;display:flex;flex-wrap:wrap;gap:16px 16px;list-style:none;margin:0;padding:0}.c-navbar__item{flex:0 0 auto}.c-navbar__link{background:0 0;border:0;color:currentcolor;display:block;text-decoration:none;text-transform:capitalize}.c-navbar__link--is-shown{text-decoration:underline}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}.c-ad--728x90 iframe{height:90px;max-width:970px}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad iframe{border:0;overflow:auto;vertical-align:top}.c-ad__label{color:#333;font-weight:400;line-height:1.5;margin-bottom:4px}.c-ad__label,.c-skip-link{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem}.c-skip-link{background:#dceaf6;bottom:auto;color:#004b83;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#004b83}.c-dropdown__button:after{border-color:transparent transparent transparent #fff;border-style:solid;border-width:4px 0 4px 14px;content:"";display:block;height:0;margin-left:3px;width:0}.c-dropdown{display:inline-block;position:relative}.c-dropdown__button{background-color:transparent;border:0;display:inline-block;padding:0;white-space:nowrap}.c-dropdown__button:after{border-color:currentcolor transparent transparent;border-width:5px 4px 0 5px;display:inline-block;margin-left:8px;vertical-align:middle}.c-dropdown__menu{background-color:#fff;border:1px solid #d9d9d9;border-radius:3px;box-shadow:0 2px 6px rgba(0,0,0,.1);font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:14px;line-height:1.4;list-style:none;margin:0;padding:8px 0;position:absolute;top:100%;transform:translateY(8px);width:180px;z-index:100}.c-dropdown__menu:after,.c-dropdown__menu:before{border-style:solid;bottom:100%;content:"";display:block;height:0;left:16px;position:absolute;width:0}.c-dropdown__menu:before{border-color:transparent transparent #d9d9d9;border-width:0 9px 9px;transform:translateX(-1px)}.c-dropdown__menu:after{border-color:transparent transparent #fff;border-width:0 8px 8px}.c-dropdown__menu--right{left:auto;right:0}.c-dropdown__menu--right:after,.c-dropdown__menu--right:before{left:auto;right:16px}.c-dropdown__menu--right:before{transform:translateX(1px)}.c-dropdown__link{background-color:transparent;color:#004b83;display:block;padding:4px 16px}.c-header{background-color:#1b3051;border-bottom:4px solid #1b3051;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:14px;padding:16px 0}.c-header__container,.c-header__menu{align-items:center;display:flex;flex-wrap:wrap}@supports (gap:2em){.c-header__container,.c-header__menu{gap:2em 2em}}.c-header__menu{list-style:none;margin:0;padding:0}.c-header__item{color:#fff}@supports not (gap:2em){.c-header__item{margin-left:24px}}.c-header__container{justify-content:space-between;margin:0 auto;max-width:1280px;padding:0 16px}@supports not (gap:2em){.c-header__brand{margin-right:48px}}.c-header__brand a{display:block;text-decoration:none}.c-header__link{color:#fff}.c-journal-title a{text-decoration:none}html.webfonts-loaded .c-journal-title{font-family:Europa,Trebuchet MS}.c-form-field{margin-bottom:1em}.c-form-field__label{color:#666;display:block;font-size:14px;margin-bottom:.4em}.c-form-field__input{border:1px solid #a6a6a6;border-radius:3px;box-shadow:inset 0 1px 3px 0 rgba(0,0,0,.21);font-size:14px;line-height:1.28571;padding:.75em 1em;vertical-align:middle;width:100%}.c-popup-search{background-color:#25426f;box-shadow:0 3px 3px -3px rgba(0,0,0,.21);padding:16px 0;position:relative;z-index:10}@media only screen and (min-width:1024px){.js .c-popup-search{position:absolute;top:100%;width:100%}.c-popup-search__container{margin:auto;max-width:70%}}.c-logo img{display:block}.ctx-search .c-form-field{margin-bottom:0}.ctx-search .c-form-field__label{color:#fff}.ctx-search .c-form-field__input{border-bottom-right-radius:0;border-top-right-radius:0;margin-right:0}.c-journal-header{overflow:hidden}.c-journal-header__inner{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-journal-header__inner{display:flex;justify-content:space-between}}.c-journal-header__identity{background-size:auto 80px;min-height:16px;padding:6px 0}@media only screen and (min-width:540px){.c-journal-header__identity{background-position:0}}.c-journal-header__identity--default{background:url(/static/images/bmc/identities/patterns/default-7e3a6b1388.svg) 0 0 no-repeat #04caa8}.c-journal-title{color:#1b3051;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:26px;font-style:normal;font-weight:700;line-height:1.4;margin-bottom:0}.c-journal-title>a{color:#0061a9;color:#1b3051;display:flex;text-decoration:none}.c-journal-title__text{align-self:center;display:block;flex:0 1 auto}.c-logo,.c-logo>a{align-items:baseline;display:flex}.c-logo__strapline{display:none}@media only screen and (min-width:540px){.c-logo__strapline{display:block;margin:0 0 0 16px;transform:translateY(1px)}}.c-logo{display:block}html.webfonts-loaded .u-h3,html.webfonts-loaded .u-h4{font-family:Europa,Trebuchet MS}.u-button{align-items:center;background-color:#f2f2f2;background-image:linear-gradient(#fff,#f2f2f2);border:1px solid #ccc;border-radius:2px;cursor:pointer;display:inline-flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button svg,.u-button--primary svg,.u-button--tertiary svg{fill:currentcolor}.u-button{color:#004b83}.u-button--primary,.u-button--tertiary{background-color:#33629d;background-image:linear-gradient(#4d76a9,#33629d);border:1px solid rgba(0,59,132,.5);color:#fff}.u-button--tertiary{font-weight:400}.u-button--full-width{display:flex;width:100%}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-display-flex{display:flex;width:100%}.u-align-items-center{align-items:center}.u-justify-content-space-between{justify-content:space-between}.u-flex-static{flex:0 0 auto}.u-display-none{display:none}.js .u-js-hide{display:none;visibility:hidden}@media print{.u-hide-print{display:none}}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-list-reset{list-style:none;margin:0;padding:0}.u-position-relative{position:relative}.u-mt-32{margin-top:32px}.u-mr-24{margin-right:24px}.u-mr-48{margin-right:48px}.u-mb-32{margin-bottom:32px}.u-ml-8{margin-left:8px}.u-button-reset{background-color:transparent;border:0;padding:0}.u-text-sm{font-size:14px}.u-h3,.u-h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;line-height:1.4}.u-h3{color:#1b3051;font-size:18px;font-style:normal;margin-bottom:.7em}.u-h4{color:#1b3051;font-size:18px;font-style:italic;font-weight:700;margin-bottom:.7em}.u-vh-full{min-height:100vh}.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}}@media only screen and (max-width:1023px){.u-hide-at-lt-lg{display:none;visibility:hidden}.u-hide-at-lt-lg:first-child+*{margin-block-start:0}}.u-visually-hidden{clip:rect(0,0,0,0);border:0;height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.u-button--tertiary{font-size:.875rem;padding:8px 16px}@media only screen and (max-width:539px){.u-button--alt-colour-on-mobile{background-color:#f2f2f2;background-image:linear-gradient(#fff,#f2f2f2);border:1px solid #ccc;color:#004b83}}body{font-size:1.125rem}.c-header__navigation{display:flex;gap:.5rem .5rem} }</style> <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) { button{line-height:inherit}html,label{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}html{-webkit-font-smoothing:subpixel-antialiased;box-sizing:border-box;color:#333;font-size:100%;height:100%;line-height:1.61803;overflow-y:scroll}*{box-sizing:inherit}body{background:#fff;margin:0;max-width:100%;min-height:100%}button,div,form,input,p{margin:0;padding:0}body{padding:0}a{color:#004b83;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}a>img{vertical-align:middle}h1,h2{color:#1b3051;font-style:normal;font-weight:700}h1{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:28px;line-height:1.4}html.webfonts-loaded h1,html.webfonts-loaded h2,html.webfonts-loaded h3{font-family:Europa,Trebuchet MS}h2{font-size:26px;margin-bottom:.5em}h2,h3{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;line-height:1.4}h3{color:#1b3051;font-size:18px;font-style:normal;margin-bottom:.7em}p{overflow-wrap:break-word;word-break:break-word}.u-h3{font-size:1.5rem}.u-h3,.u-h4{font-weight:700}.u-h4{font-size:1.25rem}.c-reading-companion__figure-title{font-size:1.25rem;font-weight:700}body{font-size:1.125rem}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin-bottom:16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#173962;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:0 0 16px}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Georgia,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;margin-top:0;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article__sub-heading{color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;font-style:normal;font-weight:400;line-height:1.3;margin:24px 0 8px}@media only screen and (min-width:768px){.c-article__sub-heading{font-size:1.5rem;line-height:1.24}}.c-article__sub-heading:first-child{margin-top:0}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#0067c5;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#0067c5;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-reading-companion__panel--active{display:block}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%;padding:13px 24px!important}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-article-associated-content__container a,.c-card__summary a{text-decoration:underline}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{clip:rect(0,0,0,0);border:0;height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-list-reset{list-style:none;margin:0;padding:0}.hide{display:none;visibility:hidden}.c-article-associated-content__container .c-article-associated-content__collection.collection~.c-article-associated-content__collection.collection .c-article-associated-content__collection-label,.c-article-associated-content__container .c-article-associated-content__collection.section~.c-article-associated-content__collection.section .c-article-associated-content__collection-label,.c-article-associated-content__container .c-article-associated-content__title{display:none}.c-article-associated-content__container .c-article-associated-content__collection.collection .c-article-associated-content__collection-label,.c-article-associated-content__container .c-article-associated-content__collection.section .c-article-associated-content__collection-label{display:block}.c-article-associated-content__container .c-article-associated-content__collection.collection,.c-article-associated-content__container .c-article-associated-content__collection.section{margin-bottom:5px}.c-article-associated-content__container .c-article-associated-content__collection.section~.c-article-associated-content__collection.collection{margin-top:28px}.c-article-associated-content__container .c-article-associated-content__collection:first-child{margin-top:0}.c-article-associated-content__container .c-article-associated-content__collection:last-child{margin-bottom:2.4rem}.c-article-associated-content__container .c-article-associated-content__collection-label{color:#1b3051}.c-article-associated-content__container .c-article-associated-content__collection-title{font-size:1.063rem;font-weight:400}.webfonts-loaded .c-article__sub-heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif} }</style> <link rel="stylesheet" data-test="critical-css-handler" data-inline-css-source="critical-css" href="/static/app-bmc/css/enhanced-32c9abc865.css" media="print" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null"> <link rel="stylesheet" data-test="critical-css-handler" data-inline-css-source="critical-css" href="/static/app-bmc/css/enhanced-article-215af16b37.css" media="print" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null"> <script type="text/javascript"> config = { env: 'live', site: 'idpjournal.biomedcentral.com', siteWithPath: 'idpjournal.biomedcentral.com' + window.location.pathname, twitterHashtag: 'idpjournal', cmsPrefix: 'https://studio-cms.springernature.com/studio/', doi: '10.1186/s40249-016-0165-2', figshareScriptUrl: 'https://widgets.figshare.com/static/figshare.js', hasFigshareInvoked: false, publisherBrand: 'BioMed Central', mustardcut: false }; </script> <script type="text/javascript" data-test="dataLayer"> window.dataLayer = [{"content":{"article":{"doi":"10.1186/s40249-016-0165-2","articleType":"Research Article","peerReviewType":"Closed","supplement":null,"keywords":"Falciparum malaria;Malaria-related anaemia;Young children;Artemisinin-based combination therapies;Nigeria"},"contentInfo":{"imprint":"BioMed Central","title":"Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under","publishedAt":1467763200000,"publishedAtDate":"2016-07-06","author":["Akintunde Sowunmi","Kazeem Akano","Adejumoke I. Ayede","Godwin Ntadom","Elsie O. Adewoye","Bayo Fatunmbi","Temitope Aderoyeje"],"collection":[]},"attributes":{"deliveryPlatform":"oscar","template":"rebrand","cms":null,"copyright":{"creativeCommonsType":"CC BY + CC0","openAccess":true},"environment":"live"},"journal":{"siteKey":"idpjournal.biomedcentral.com","volume":"5","issue":"1","title":"Infectious Diseases of Poverty","type":"BMC AJs","journalID":40249,"section":[]},"category":{"pmc":{"primarySubject":"Medicine & Public Health"},"contentType":"Research Article","publishingSegment":"BMC AJ6","snt":["Diseases","Tropical Medicine","Public Health"]}},"session":{"authentication":{"authenticationID":[]}},"version":"1.0.0","page":{"category":{"pageType":"article"},"attributes":{"featureFlags":[],"environment":"live","darwin":false}},"japan":false,"event":"dataLayerCreated","collection":null,"publisherBrand":"BioMed Central"}]; </script> <script> window.dataLayer = window.dataLayer || []; window.dataLayer.push({ ga4MeasurementId: 'G-PJCTJWPV25', ga360TrackingId: 'UA-54492316-9', twitterId: 'o47a2', baiduId: 'd1b4bc3b5ada4eb7290535e72899bac1', ga4ServerUrl: 'https://collect.biomedcentral.com', imprint: 'biomedcentral' }); </script> <script> (function(w, d) { w.config = w.config || {}; w.config.mustardcut = false; if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) { w.config.mustardcut = true; d.classList.add('js'); d.classList.remove('grade-c'); d.classList.remove('no-js'); } })(window, document.documentElement); </script> <script> (function () { if ( typeof window.CustomEvent === "function" ) return false; function CustomEvent ( event, params ) { params = params || { bubbles: false, cancelable: false, detail: null }; var evt = document.createEvent( 'CustomEvent' ); evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail ); return evt; } CustomEvent.prototype = window.Event.prototype; window.CustomEvent = CustomEvent; })(); </script> <script class="js-entry"> if (window.config.mustardcut) { (function(w, d) { window.Component = {}; window.suppressShareButton = true; window.onArticlePage = true; var currentScript = d.currentScript || d.head.querySelector('script.js-entry'); function catchNoModuleSupport() { var scriptEl = d.createElement('script'); return (!('noModule' in scriptEl) && 'onbeforeload' in scriptEl) } var headScripts = [ {'src': '/static/js/polyfill-es5-bundle-572d4fec60.js', 'async': false} ]; var bodyScripts = [ {'src': '/static/js/app-es5-bundle-d0ac94c97e.js', 'async': false, 'module': false}, {'src': '/static/js/app-es6-bundle-5ee1a6879c.js', 'async': false, 'module': true} , {'src': '/static/js/global-article-es5-bundle-ae3b685a1c.js', 'async': false, 'module': false}, {'src': '/static/js/global-article-es6-bundle-f72e3cd2ca.js', 'async': false, 'module': true} ]; function createScript(script) { var scriptEl = d.createElement('script'); scriptEl.src = script.src; scriptEl.async = script.async; if (script.module === true) { scriptEl.type = "module"; if (catchNoModuleSupport()) { scriptEl.src = ''; } } else if (script.module === false) { scriptEl.setAttribute('nomodule', true) } if (script.charset) { scriptEl.setAttribute('charset', script.charset); } return scriptEl; } for (var i = 0; i < headScripts.length; ++i) { var scriptEl = createScript(headScripts[i]); currentScript.parentNode.insertBefore(scriptEl, currentScript.nextSibling); } d.addEventListener('DOMContentLoaded', function() { for (var i = 0; i < bodyScripts.length; ++i) { var scriptEl = createScript(bodyScripts[i]); d.body.appendChild(scriptEl); } }); // Webfont repeat view var config = w.config; if (config && config.publisherBrand && sessionStorage.fontsLoaded === 'true') { d.documentElement.className += ' webfonts-loaded'; } })(window, document); } </script> <script data-src="https://cdn.optimizely.com/js/27195530232.js" data-cc-script="C03"></script> <script data-test="gtm-head"> window.initGTM = function() { (function (w, d, s, l, i) { w[l] = w[l] || []; w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'}); var f = d.getElementsByTagName(s)[0], j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f); })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ'); } </script> <meta name="360-site-verification" content="2e1d87196f82c9ac5454a21aede69eda" /> <script> (function (w, d, t) { function cc() { var h = w.location.hostname; var e = d.createElement(t), s = d.getElementsByTagName(t)[0]; if (h.indexOf('springer.com') > -1 && h.indexOf('biomedcentral.com') === -1 && h.indexOf('springeropen.com') === -1) { if (h.indexOf('link-qa.springer.com') > -1 || h.indexOf('test-www.springer.com') > -1) { e.src = 'https://cmp.springer.com/production_live/en/consent-bundle-17-52.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"); } else { e.src = 'https://cmp.springer.com/production_live/en/consent-bundle-17-52.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"); } } else if (h.indexOf('biomedcentral.com') > -1) { if (h.indexOf('biomedcentral.com.qa') > -1) { e.src = 'https://cmp.biomedcentral.com/production_live/en/consent-bundle-15-36.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"); } else { e.src = 'https://cmp.biomedcentral.com/production_live/en/consent-bundle-15-36.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"); } } else if (h.indexOf('springeropen.com') > -1) { if (h.indexOf('springeropen.com.qa') > -1) { e.src = 'https://cmp.springernature.com/production_live/en/consent-bundle-16-35.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"); } else { e.src = 'https://cmp.springernature.com/production_live/en/consent-bundle-16-35.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"); } } else if (h.indexOf('springernature.com') > -1) { if (h.indexOf('beta-qa.springernature.com') > -1) { e.src = 'https://cmp.springernature.com/production_live/en/consent-bundle-49-43.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-NK22KLS')"); } else { e.src = 'https://cmp.springernature.com/production_live/en/consent-bundle-49-43.js'; e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-NK22KLS')"); } } else { e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js'; e.setAttribute('data-consent', h); } s.insertAdjacentElement('afterend', e); } cc(); })(window, document, 'script'); </script> <link rel="canonical" href="https://idpjournal.biomedcentral.com/articles/10.1186/s40249-016-0165-2"/> <meta property="og:url" content="https://idpjournal.biomedcentral.com/articles/10.1186/s40249-016-0165-2"/> <meta property="og:type" content="article"/> <meta property="og:site_name" content="BioMed Central"/> <meta property="og:title" content="Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under - Infectious Diseases of Poverty"/> <meta property="og:description" content="Background Artemisinin-based combination therapies are recommended as first-line treatments for uncomplicated falciparum malaria, but there is little evaluation of their efficacy and effects on uncomplicated malaria-associated anaemia in children aged 2 years and under. Methods Parasitological efficacy and effects on malaria-associated anaemia were evaluated in 250 malarious children aged 2 years and under, and efficacy was evaluated in 603 malarious children older than two but younger than 5 years of age following treatment with artesunate-amodiaquine (AA) or artemether-lumefantrine (AL). Kinetics of the disposition of parasitaemia following treatment were evaluated using a non-compartment model. Late-appearing anaemia (LAA) was diagnosed using the following criteria: clearance of parasitaemia, fever and other symptoms occurring within 7 days of starting treatment, adequate clinical and parasitological response on days 28–42, haematocrit (HCT) ≥ 30 % at 1 and/or 2 weeks, a fall in HCT to < 30 % occurring at 3–6 weeks, absence of concomitant illness at 1–6 weeks, and absence of asexual parasitaemia detected using both microscopy and polymerase chain reaction (PCR) at 1–6 weeks. Results Overall, in children aged 2 years and under, the PCR-corrected parasitological efficacy was 97.2 % (95 % CI 92.8–101.6), which was similar for both treatments. In children older than 2 years, parasitological efficacy was also similar for both treatments, but parasite prevalence 1 day after treatment began was significantly higher, and fever and parasite clearance times were significantly faster in the AA-treated children compared with the AL-treated children. Declines in parasitaemia were monoexponential with an estimated elimination half-time of 1 h. Elimination half-times were similar for both treatments. In children aged 2 years and under who were anaemic at presentation, the mean anaemia recovery time was 12.1 days (95 % CI 10.6–13.6, n = 127), which was similar for both treatments. Relatively asymptomatic LAA occurred in 11 children (4.4 %) aged 2 years and under, the recovery from which was uneventful. Conclusion This study showed that AA and AL are efficacious treatments for uncomplicated falciparum malaria in Nigerian children aged 2 years and under, and that AA clears parasitaemia and fever significantly faster than AL in children older than 2 years. Both treatments may cause a relatively asymptomatic LAA with uneventful recovery in a small proportion of children aged 2 years and under. Trials registration Pan African Clinical Trial Registry PACTR201508001188143, 3 July 2015; PACTR201510001189370, 3 July 2015; PACTR201508001191898, 7 July 2015 and PACTR201508001193368, 8 July 2015 http://www.pactr.org ."/> <meta property="og:image" content="https://static-content.springer.com/image/art%3A10.1186%2Fs40249-016-0165-2/MediaObjects/40249_2016_165_Fig1_HTML.gif"/> <script type="application/ld+json">{"mainEntity":{"headline":"Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under","description":"Artemisinin-based combination therapies are recommended as first-line treatments for uncomplicated falciparum malaria, but there is little evaluation of their efficacy and effects on uncomplicated malaria-associated anaemia in children aged 2 years and under. Parasitological efficacy and effects on malaria-associated anaemia were evaluated in 250 malarious children aged 2 years and under, and efficacy was evaluated in 603 malarious children older than two but younger than 5 years of age following treatment with artesunate-amodiaquine (AA) or artemether-lumefantrine (AL). Kinetics of the disposition of parasitaemia following treatment were evaluated using a non-compartment model. Late-appearing anaemia (LAA) was diagnosed using the following criteria: clearance of parasitaemia, fever and other symptoms occurring within 7 days of starting treatment, adequate clinical and parasitological response on days 28–42, haematocrit (HCT) ≥ 30 % at 1 and/or 2 weeks, a fall in HCT to < 30 % occurring at 3–6 weeks, absence of concomitant illness at 1–6 weeks, and absence of asexual parasitaemia detected using both microscopy and polymerase chain reaction (PCR) at 1–6 weeks. Overall, in children aged 2 years and under, the PCR-corrected parasitological efficacy was 97.2 % (95 % CI 92.8–101.6), which was similar for both treatments. In children older than 2 years, parasitological efficacy was also similar for both treatments, but parasite prevalence 1 day after treatment began was significantly higher, and fever and parasite clearance times were significantly faster in the AA-treated children compared with the AL-treated children. Declines in parasitaemia were monoexponential with an estimated elimination half-time of 1 h. Elimination half-times were similar for both treatments. In children aged 2 years and under who were anaemic at presentation, the mean anaemia recovery time was 12.1 days (95 % CI 10.6–13.6, n = 127), which was similar for both treatments. Relatively asymptomatic LAA occurred in 11 children (4.4 %) aged 2 years and under, the recovery from which was uneventful. This study showed that AA and AL are efficacious treatments for uncomplicated falciparum malaria in Nigerian children aged 2 years and under, and that AA clears parasitaemia and fever significantly faster than AL in children older than 2 years. Both treatments may cause a relatively asymptomatic LAA with uneventful recovery in a small proportion of children aged 2 years and under. Pan African Clinical Trial Registry PACTR201508001188143, 3 July 2015; PACTR201510001189370, 3 July 2015; PACTR201508001191898, 7 July 2015 and PACTR201508001193368, 8 July 2015 \n http://www.pactr.org\n \n .","datePublished":"2016-07-06T00:00:00Z","dateModified":"2016-07-06T00:00:00Z","pageStart":"1","pageEnd":"14","license":"http://creativecommons.org/publicdomain/zero/1.0/","sameAs":"https://doi.org/10.1186/s40249-016-0165-2","keywords":["Falciparum malaria","Malaria-related anaemia","Young children","Artemisinin-based combination therapies","Nigeria","Infectious Diseases","Tropical Medicine","Public Health"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40249-016-0165-2/MediaObjects/40249_2016_165_Fig1_HTML.gif","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40249-016-0165-2/MediaObjects/40249_2016_165_Fig2_HTML.gif","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40249-016-0165-2/MediaObjects/40249_2016_165_Fig3_HTML.gif"],"isPartOf":{"name":"Infectious Diseases of Poverty","issn":["2049-9957"],"volumeNumber":"5","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"BioMed Central","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Akintunde Sowunmi","affiliation":[{"name":"University of Ibadan","address":{"name":"Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Ibadan","address":{"name":"Institute for Medical Research and Training, University of Ibadan, Ibadan, Nigeria","@type":"PostalAddress"},"@type":"Organization"}],"email":"akinsowunmi@hotmail.com","@type":"Person"},{"name":"Kazeem Akano","affiliation":[{"name":"University of Ibadan","address":{"name":"Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Adejumoke I. Ayede","affiliation":[{"name":"University of Ibadan","address":{"name":"Department of Paediatrics, University of Ibadan, Ibadan, Nigeria","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Godwin Ntadom","affiliation":[{"name":"Malaria Elimination Programme, Federal Ministry of Health","address":{"name":"Malaria Elimination Programme, Federal Ministry of Health, Abuja, Nigeria","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Elsie O. Adewoye","affiliation":[{"name":"University of Ibadan","address":{"name":"Department of Physiology, University of Ibadan, Ibadan, Nigeria","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Bayo Fatunmbi","affiliation":[{"name":"World Health Organization, Regional Office for the Western Pacific","address":{"name":"World Health Organization, Regional Office for the Western Pacific, Phnom Penh, Cambodia","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Temitope Aderoyeje","affiliation":[{"name":"University College Hospital","address":{"name":"Department of Clinical Pharmacology, University College Hospital, Ibadan, Nigeria","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script> </head> <body class="journal journal-fulltext" > <div class="ctm"></div> <!-- Google Tag Manager (noscript) --> <noscript> <iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ" height="0" width="0" style="display:none;visibility:hidden"></iframe> </noscript> <!-- End Google Tag Manager (noscript) --> <div class="u-visually-hidden" aria-hidden="true"> <?xml version="1.0" encoding="UTF-8"?><!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"/></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"/></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"/></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"/></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"/></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"/></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"/></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"/></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"/></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"/></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"/></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"/></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"/></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"/></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"/></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"/></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"/></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"/></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"/></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"/></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"/></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"/></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"/></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"/></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"/></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"/></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"/></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"/></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"/></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"/></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"/></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"/></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"/></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"/></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"/></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"/></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"/></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"/></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"/></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"/></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"/></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"/></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"/></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"/></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-left-bullet" viewBox="0 0 8 16"><path d="M3 8l5 5v3L0 8l8-8v3L3 8z"/></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 3)"/></symbol><symbol id="icon-download-rounded"><path d="M0 13c0-.556.449-1 1.002-1h9.996a.999.999 0 110 2H1.002A1.006 1.006 0 010 13zM7 1v6.8l2.482-2.482c.392-.392 1.022-.4 1.403-.02a1.001 1.001 0 010 1.417l-4.177 4.177a1.001 1.001 0 01-1.416 0L1.115 6.715a.991.991 0 01-.016-1.4 1 1 0 011.42.003L5 7.8V1c0-.55.444-.996 1-.996.552 0 1 .445 1 .996z"/></symbol><symbol id="icon-ext-link" viewBox="0 0 16 16"><path d="M12.9 16H3.1C1.4 16 0 14.6 0 12.9V3.2C0 1.4 1.4 0 3.1 0h3.7v1H3.1C2 1 1 2 1 3.2v9.7C1 14 2 15 3.1 15h9.7c1.2 0 2.1-1 2.1-2.1V8.7h1v4.2c.1 1.7-1.3 3.1-3 3.1z"/><path d="M12.8 2.5l.7.7-9 8.9-.7-.7 9-8.9z"/><path d="M9.7 0L16 6.2V0z"/></symbol><symbol id="icon-remove" viewBox="-296 388 18 18"><path d="M-291.7 396.1h9v2h-9z"/><path d="M-287 405.5c-4.7 0-8.5-3.8-8.5-8.5s3.8-8.5 8.5-8.5 8.5 3.8 8.5 8.5-3.8 8.5-8.5 8.5zm0-16c-4.1 0-7.5 3.4-7.5 7.5s3.4 7.5 7.5 7.5 7.5-3.4 7.5-7.5-3.4-7.5-7.5-7.5z"/></symbol><symbol id="icon-rss" viewBox="0 0 18 18"><path d="m.97480857 6.01583891.11675372.00378391c5.75903295.51984988 10.34261021 5.10537458 10.85988231 10.86480098.0494035.5500707-.3564674 1.0360406-.906538 1.0854441-.5500707.0494036-1.0360406-.3564673-1.08544412-.906538-.43079083-4.7965248-4.25151132-8.61886853-9.04770289-9.05180573-.55004837-.04965115-.95570047-.53580366-.90604933-1.08585203.04610464-.5107592.46858035-.89701345.96909831-.90983323zm1.52519143 6.95474179c1.38071187 0 2.5 1.1192881 2.5 2.5s-1.11928813 2.5-2.5 2.5-2.5-1.1192881-2.5-2.5 1.11928813-2.5 2.5-2.5zm-1.43253846-12.96884168c9.09581416.53242539 16.37540296 7.8163886 16.90205336 16.91294558.0319214.5513615-.389168 1.0242056-.9405294 1.056127-.5513615.0319214-1.0242057-.389168-1.0561271-.9405294-.4679958-8.08344784-6.93949306-14.55883389-15.02226722-15.03196077-.55134101-.03227286-.97212889-.50538538-.93985602-1.05672639.03227286-.551341.50538538-.97212888 1.05672638-.93985602z" fill-rule="evenodd"/></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"/></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"/></symbol><symbol id="icon-springer-collections" viewBox="3 3 32 32"><path fill-rule="evenodd" d="M25.583333,30.1249997 L25.583333,7.1207574 C25.583333,7.10772495 25.579812,7.10416665 25.5859851,7.10416665 L6.10400517,7.10571021 L6.10400517,30.1355179 C6.10400517,31.1064087 6.89406744,31.8958329 7.86448169,31.8958329 L26.057145,31.8958329 C25.7558021,31.374901 25.583333,30.7700915 25.583333,30.1249997 Z M4.33333333,30.1355179 L4.33333333,7.10571021 C4.33333333,6.12070047 5.12497502,5.33333333 6.10151452,5.33333333 L25.5859851,5.33333333 C26.5617372,5.33333333 27.3541664,6.13359035 27.3541664,7.1207574 L27.3541664,12.4166666 L32.6666663,12.4166666 L32.6666663,30.1098941 C32.6666663,32.0694626 31.0857174,33.6666663 29.1355179,33.6666663 L7.86448169,33.6666663 C5.91736809,33.6666663 4.33333333,32.0857174 4.33333333,30.1355179 Z M27.3541664,14.1874999 L27.3541664,30.1249997 C27.3541664,31.1030039 28.1469954,31.8958329 29.1249997,31.8958329 C30.1030039,31.8958329 30.8958329,31.1030039 30.8958329,30.1249997 L30.8958329,14.1874999 L27.3541664,14.1874999 Z M9.64583326,10.6458333 L22.0416665,10.6458333 L22.0416665,17.7291665 L9.64583326,17.7291665 L9.64583326,10.6458333 Z M11.4166666,12.4166666 L11.4166666,15.9583331 L20.2708331,15.9583331 L20.2708331,12.4166666 L11.4166666,12.4166666 Z M9.64583326,19.4999998 L22.0416665,19.4999998 L22.0416665,21.2708331 L9.64583326,21.2708331 L9.64583326,19.4999998 Z M9.64583326,23.0416665 L22.0416665,23.0416665 L22.0416665,24.8124997 L9.64583326,24.8124997 L9.64583326,23.0416665 Z M9.64583326,26.583333 L22.0416665,26.583333 L22.0416665,28.3541664 L9.64583326,28.3541664 L9.64583326,26.583333 Z"/></symbol><symbol id="icon-springer-download" viewBox="-301 390 9 14"><path d="M-301 395.6l4.5 5.1 4.5-5.1h-3V390h-3v5.6h-3zm0 6.5h9v1.9h-9z"/></symbol><symbol id="icon-springer-info" viewBox="0 0 24 24"><!--Generator: Sketch 63.1 (92452) - https://sketch.com--><g id="V&I" stroke="none" stroke-width="1" fill-rule="evenodd"><g id="info" fill-rule="nonzero"><path d="M12,0 C18.627417,0 24,5.372583 24,12 C24,18.627417 18.627417,24 12,24 C5.372583,24 0,18.627417 0,12 C0,5.372583 5.372583,0 12,0 Z M12.5540543,9.1 L11.5540543,9.1 C11.0017696,9.1 10.5540543,9.54771525 10.5540543,10.1 L10.5540543,10.1 L10.5540543,18.1 C10.5540543,18.6522847 11.0017696,19.1 11.5540543,19.1 L11.5540543,19.1 L12.5540543,19.1 C13.1063391,19.1 13.5540543,18.6522847 13.5540543,18.1 L13.5540543,18.1 L13.5540543,10.1 C13.5540543,9.54771525 13.1063391,9.1 12.5540543,9.1 L12.5540543,9.1 Z M12,5 C11.5356863,5 11.1529412,5.14640523 10.8517647,5.43921569 C10.5505882,5.73202614 10.4,6.11546841 10.4,6.58954248 C10.4,7.06361656 10.5505882,7.45054466 10.8517647,7.7503268 C11.1529412,8.05010893 11.5356863,8.2 12,8.2 C12.4768627,8.2 12.8627451,8.05010893 13.1576471,7.7503268 C13.452549,7.45054466 13.6,7.06361656 13.6,6.58954248 C13.6,6.11546841 13.452549,5.73202614 13.1576471,5.43921569 C12.8627451,5.14640523 12.4768627,5 12,5 Z" id="Combined-Shape"/></g></g></symbol><symbol id="icon-springer-tick-circle" viewBox="0 0 24 24"><g id="Page-1" stroke="none" stroke-width="1" fill-rule="evenodd"><g id="springer-tick-circle" fill-rule="nonzero"><path d="M12,24 C5.372583,24 0,18.627417 0,12 C0,5.372583 5.372583,0 12,0 C18.627417,0 24,5.372583 24,12 C24,18.627417 18.627417,24 12,24 Z M7.657,10.79 C7.45285634,10.6137568 7.18569967,10.5283283 6.91717333,10.5534259 C6.648647,10.5785236 6.40194824,10.7119794 6.234,10.923 C5.87705269,11.3666969 5.93445559,12.0131419 6.364,12.387 L10.261,15.754 C10.6765468,16.112859 11.3037113,16.0695601 11.666,15.657 L17.759,8.713 C18.120307,8.27302248 18.0695334,7.62621189 17.644,7.248 C17.4414817,7.06995024 17.1751516,6.9821166 16.9064461,7.00476032 C16.6377406,7.02740404 16.3898655,7.15856958 16.22,7.368 L10.768,13.489 L7.657,10.79 Z" id="path-1"/></g></g></symbol><symbol id="icon-updates" viewBox="0 0 18 18"><g fill-rule="nonzero"><path d="M16.98 3.484h-.48c-2.52-.058-5.04 1.161-7.44 2.903-2.46-1.8-4.74-2.903-8.04-2.903-.3 0-.54.29-.54.58v9.813c0 .29.24.523.54.581 2.76.348 4.86 1.045 7.62 2.903.24.116.54.116.72 0 2.76-1.858 4.86-2.555 7.62-2.903.3-.058.54-.29.54-.58V4.064c0-.29-.24-.523-.54-.581zm-15.3 1.22c2.34 0 4.86 1.509 6.72 2.786v8.478c-2.34-1.394-4.38-2.09-6.72-2.439V4.703zm14.58 8.767c-2.34.348-4.38 1.045-6.72 2.439V7.374C12 5.632 14.1 4.645 16.26 4.645v8.826z"/><path d="M9 .058c-1.56 0-2.76 1.22-2.76 2.671C6.24 4.181 7.5 5.4 9 5.4c1.5 0 2.76-1.22 2.76-2.671 0-1.452-1.2-2.67-2.76-2.67zm0 4.413c-.96 0-1.8-.755-1.8-1.742C7.2 1.8 7.98.987 9 .987s1.8.755 1.8 1.742c0 .93-.84 1.742-1.8 1.742z"/></g></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"/><clipPath id="b"><use xlink:href="#a" style="overflow:visible"/></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"/><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"/></symbol><symbol id="icon-submit-closed" viewBox="0 0 18 18"><path d="m15 0c1.1045695 0 2 .8954305 2 2v4.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-4.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h4.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-4.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-2.5 7c3.0375661 0 5.5 2.46243388 5.5 5.5 0 3.0375661-2.4624339 5.5-5.5 5.5-3.03756612 0-5.5-2.4624339-5.5-5.5 0-3.03756612 2.46243388-5.5 5.5-5.5zm0 1c-2.4852814 0-4.5 2.0147186-4.5 4.5s2.0147186 4.5 4.5 4.5 4.5-2.0147186 4.5-4.5-2.0147186-4.5-4.5-4.5zm2.3087379 2.1912621c.2550161.2550162.2550161.668479 0 .9234952l-1.3859024 1.3845831 1.3859024 1.3859023c.2550161.2550162.2550161.668479 0 .9234952-.2550162.2550161-.668479.2550161-.9234952 0l-1.3859023-1.3859024-1.3845831 1.3859024c-.2550162.2550161-.668479.2550161-.9234952 0-.25501614-.2550162-.25501614-.668479 0-.9234952l1.3845831-1.3859023-1.3845831-1.3845831c-.25501614-.2550162-.25501614-.668479 0-.9234952.2550162-.25501614.668479-.25501614.9234952 0l1.3845831 1.3845831 1.3859023-1.3845831c.2550162-.25501614.668479-.25501614.9234952 0zm-9.8087379-8.7782621-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1z"/></symbol><symbol id="icon-submit-open" viewBox="0 0 18 18"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z"/></symbol><symbol id="icon-submit-upcoming" viewBox="0 0 18 18"><path d="m15 0c1.1045695 0 2 .8954305 2 2v4.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-4.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h4.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-4.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-2.5 7c3.0375661 0 5.5 2.46243388 5.5 5.5 0 3.0375661-2.4624339 5.5-5.5 5.5-3.03756612 0-5.5-2.4624339-5.5-5.5 0-1.6607442.73606908-3.14957021 1.89976608-4.15803695l-1.51549374.02214397c-.27613212.00263356-.49998143-.22483432-.49998143-.49020681 0-.24299316.17766103-.44509007.40961587-.48700057l.08928713-.00797472h2.66407569c.2449213 0 .4486219.17766776.490865.40963137l.008038.08929051v2.6642143c0 .275547-.2296028.4989219-.4949753.4989219-.24299317 0-.44342617-.1744719-.4830969-.4093269l-.00710993-.0906783.01983146-1.46576707c-.96740882.82538117-1.58082193 2.05345007-1.58082193 3.42478927 0 2.4852814 2.0147186 4.5 4.5 4.5s4.5-2.0147186 4.5-4.5-2.0147186-4.5-4.5-4.5c-.7684937 0-.7684937-1 0-1zm0 2.85c.3263501 0 .5965265.2405082.6429523.5539478l.0070477.0960522v1.731l.8096194.8093806c.2284567.2284567.2513024.5846637.068537.8386705l-.068537.0805683c-.2284567.2284567-.5846637.2513024-.8386705.068537l-.0805683-.068537-.9707107-.9707107c-.1125218-.1125218-.1855975-.257116-.2103268-.412296l-.0093431-.1180341v-1.9585786c0-.3589851.2910149-.65.65-.65zm-7.5-8.437-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1z"/></symbol><symbol id="icon-facebook-bordered" viewBox="463.812 263.868 32 32"><path d="M479.812,263.868c-8.837,0-16,7.163-16,16s7.163,16,16,16s16-7.163,16-16S488.649,263.868,479.812,263.868z M479.812,293.868c-7.732,0-14-6.269-14-14s6.268-14,14-14s14,6.269,14,14S487.545,293.868,479.812,293.868z"/><path d="M483.025,280.48l0.32-2.477h-2.453v-1.582c0-0.715,0.199-1.207,1.227-1.207h1.311v-2.213 c-0.227-0.029-1.003-0.098-1.907-0.098c-1.894,0-3.186,1.154-3.186,3.271v1.826h-2.142v2.477h2.142v6.354h2.557v-6.354 L483.025,280.48L483.025,280.48z"/></symbol><symbol id="icon-twitter-bordered" viewBox="463.812 263.868 32 32"><g><path d="M486.416,276.191c-0.483,0.215-1.007,0.357-1.554,0.429c0.558-0.338,0.991-0.868,1.19-1.502 c-0.521,0.308-1.104,0.536-1.72,0.657c-0.494-0.526-1.2-0.854-1.979-0.854c-1.496,0-2.711,1.213-2.711,2.71 c0,0.212,0.023,0.419,0.069,0.616c-2.252-0.111-4.25-1.19-5.586-2.831c-0.231,0.398-0.365,0.866-0.365,1.361 c0,0.94,0.479,1.772,1.204,2.257c-0.441-0.015-0.861-0.138-1.227-0.339v0.031c0,1.314,0.937,2.41,2.174,2.656 c-0.227,0.062-0.47,0.098-0.718,0.098c-0.171,0-0.343-0.018-0.511-0.049c0.35,1.074,1.347,1.859,2.531,1.883 c-0.928,0.726-2.095,1.16-3.366,1.16c-0.22,0-0.433-0.014-0.644-0.037c1.2,0.768,2.621,1.215,4.155,1.215 c4.983,0,7.71-4.129,7.71-7.711c0-0.115-0.004-0.232-0.006-0.351C485.592,277.212,486.054,276.734,486.416,276.191z"/></g><path d="M479.812,263.868c-8.837,0-16,7.163-16,16s7.163,16,16,16s16-7.163,16-16S488.649,263.868,479.812,263.868z M479.812,293.868c-7.732,0-14-6.269-14-14s6.268-14,14-14s14,6.269,14,14S487.545,293.868,479.812,293.868z"/></symbol><symbol id="icon-weibo-bordered" viewBox="463.812 263.868 32 32"><path d="M479.812,263.868c-8.838,0-16,7.163-16,16s7.162,16,16,16c8.837,0,16-7.163,16-16S488.649,263.868,479.812,263.868z M479.812,293.868c-7.732,0-14-6.269-14-14s6.268-14,14-14c7.731,0,14,6.269,14,14S487.545,293.868,479.812,293.868z"/><g><path d="M478.552,285.348c-2.616,0.261-4.876-0.926-5.044-2.649c-0.167-1.722,1.814-3.33,4.433-3.588 c2.609-0.263,4.871,0.926,5.041,2.647C483.147,283.479,481.164,285.089,478.552,285.348 M483.782,279.63 c-0.226-0.065-0.374-0.109-0.259-0.403c0.25-0.639,0.276-1.188,0.005-1.581c-0.515-0.734-1.915-0.693-3.521-0.021 c0,0-0.508,0.224-0.378-0.181c0.247-0.798,0.209-1.468-0.178-1.852c-0.87-0.878-3.194,0.032-5.183,2.027 c-1.489,1.494-2.357,3.082-2.357,4.453c0,2.619,3.354,4.213,6.631,4.213c4.297,0,7.154-2.504,7.154-4.493 C485.697,280.594,484.689,279.911,483.782,279.63"/><path d="M486.637,274.833c-1.039-1.154-2.57-1.592-3.982-1.291l0,0c-0.325,0.068-0.532,0.391-0.465,0.72 c0.068,0.328,0.391,0.537,0.72,0.466c1.005-0.215,2.092,0.104,2.827,0.92c0.736,0.818,0.938,1.939,0.625,2.918l0,0 c-0.102,0.318,0.068,0.661,0.39,0.762c0.32,0.104,0.658-0.069,0.763-0.391v-0.001C487.953,277.558,487.674,275.985,486.637,274.833 "/><path d="M485.041,276.276c-0.504-0.562-1.25-0.774-1.938-0.63c-0.279,0.06-0.461,0.339-0.396,0.621 c0.062,0.281,0.335,0.461,0.617,0.398l0,0c0.336-0.071,0.702,0.03,0.947,0.307s0.312,0.649,0.207,0.979l0,0 c-0.089,0.271,0.062,0.565,0.336,0.654c0.274,0.09,0.564-0.062,0.657-0.336C485.686,277.604,485.549,276.837,485.041,276.276"/><path d="M478.694,282.227c-0.09,0.156-0.293,0.233-0.451,0.166c-0.151-0.062-0.204-0.235-0.115-0.389 c0.093-0.155,0.284-0.229,0.44-0.168C478.725,281.892,478.782,282.071,478.694,282.227 M477.862,283.301 c-0.253,0.405-0.795,0.58-1.202,0.396c-0.403-0.186-0.521-0.655-0.27-1.051c0.248-0.39,0.771-0.566,1.176-0.393 C477.979,282.423,478.109,282.889,477.862,283.301 M478.812,280.437c-1.244-0.326-2.65,0.294-3.19,1.396 c-0.553,1.119-0.021,2.369,1.236,2.775c1.303,0.42,2.84-0.225,3.374-1.436C480.758,281.989,480.1,280.77,478.812,280.437"/></g></symbol></svg> </div> <div class="u-vh-full"> <a class="c-skip-link" href="#main-content">Skip to main content</a> <div class="u-hide u-show-following-ad"></div> <aside class="adsbox c-ad c-ad--728x90" data-component-mpu> <div class="c-ad__inner"> <p class="c-ad__label">Advertisement</p> <div id="div-gpt-ad-LB1" data-ad-type="LB1" data-test="LB1-ad" data-pa11y-ignore data-gpt data-gpt-unitpath="/270604982/bmc/idpjournal/articles" data-gpt-sizes="728x90,970x90" data-gpt-targeting="pos=LB1;doi=10.1186/s40249-016-0165-2;type=article;kwrd=Falciparum malaria,Malaria-related anaemia,Young children,Artemisinin-based combination therapies,Nigeria;pmc=H33096,H61006,H27002;" > <noscript> <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/270604982/bmc/idpjournal/articles&sz=728x90,970x90&pos=LB1&doi=10.1186/s40249-016-0165-2&type=article&kwrd=Falciparum malaria,Malaria-related anaemia,Young children,Artemisinin-based combination therapies,Nigeria&pmc=H33096,H61006,H27002&"> <img data-test="gpt-advert-fallback-img" src="//pubads.g.doubleclick.net/gampad/ad?iu=/270604982/bmc/idpjournal/articles&sz=728x90,970x90&pos=LB1&doi=10.1186/s40249-016-0165-2&type=article&kwrd=Falciparum malaria,Malaria-related anaemia,Young children,Artemisinin-based combination therapies,Nigeria&pmc=H33096,H61006,H27002&" alt="Advertisement" width="728" height="90"> </a> </noscript> </div> </div> </aside> <div id="membership-message-loader-desktop" class="placeholder" data-placeholder="/placeholder/v1/membership/message"></div> <div id="top" class="u-position-relative"> <header class="c-header" data-test="publisher-header"> <div class="c-header__container"> <div class="c-header__brand u-mr-48" itemscope itemtype="http://schema.org/Organization" data-test="navbar-logo-header"> <div class="c-logo"> <a href="https://www.biomedcentral.com" itemprop="url"> <img alt="BMC" itemprop="logo" width="76" height="18" role="img" src=/static/images/bmc/logos/logo-bmc-white-aj-be532aa3f0.svg> <div class="c-logo__strapline"> <img alt="Part of Springer Nature" width="173" height="16" role="img" src=/static/images/bmc/logos/logo-bmc-white-strapline-sn-f224388d67.svg> </div> </a> </div> </div> <div class="c-header__navigation"> <button type="button" class="c-header__link u-button-reset u-mr-24" data-expander data-expander-target="#publisher-header-search" data-expander-autofocus="firstTabbable" data-test="header-search-button" aria-controls="publisher-header-search" aria-expanded="false"> <span class="u-display-flex u-align-items-center"> <span>Search</span> <svg class="u-icon u-flex-static u-ml-8" aria-hidden="true" focusable="false"> <use xlink:href="#icon-search"></use> </svg> </span> </button> <nav> <ul class="c-header__menu" data-enhanced-menu data-test="publisher-navigation"> <li class="c-header__item u-hide-at-lt-lg"> <a class="c-header__link" href="//www.biomedcentral.com/journals"> Explore journals </a> </li> <li class="c-header__item u-hide-at-lt-lg"> <a class="c-header__link" href="//www.biomedcentral.com/getpublished"> Get published </a> </li> <li class="c-header__item u-hide-at-lt-lg"> <a class="c-header__link" href="//www.biomedcentral.com/about"> About BMC </a> </li> <li class="c-header__item"> <a data-enhanced-account class="c-header__link" href="https://www.biomedcentral.com/account" data-test="login-link"> My account </a> </li> </ul> </nav> </div> </div> </header> <div class="c-popup-search u-js-hide" id="publisher-header-search"> <div class="u-container"> <div class="c-popup-search__container"> <div class="ctx-search"> <form role="search" class="c-form-field js-skip-validation" method="GET" action="//www.biomedcentral.com/search" data-track="search" data-track-context="pop out website-wide search in bmc website header" data-track-category="Search and Results" data-track-action="Submit search" data-dynamic-track-label data-track-label="" data-test="global-search"> <label for="publisherSearch" class="c-form-field__label">Search all BMC articles</label> <div class="u-display-flex"> <input id="publisherSearch" class="c-form-field__input" data-search-input autocomplete="off" role="textbox" data-test="search-input" name="query" type="text" value=""/> <div> <button class="u-button" type="submit" data-test="search-submit-button"> <span class="u-visually-hidden">Search</span> <svg class="u-icon u-flex-static" width="16" height="16" aria-hidden="true" focusable="false"> <use xlink:href="#icon-search"></use> </svg> </button> </div> </div> <input type="hidden" name="searchType" value="publisherSearch"/> </form> </div> </div> </div> </div> </div> <header class="c-journal-header c-journal-header--infectious-diseases-of-poverty ctx-journal-header"> <div class="u-container"> <div class="c-journal-header__inner "> <div class="c-journal-title" id="journalTitle"> <a href="/"> <span class="c-journal-title__text ">Infectious Diseases of Poverty</span> </a> </div> </div> </div> <div class="c-navbar c-navbar--with-submit-button"> <div class="c-navbar__container"> <div class="c-navbar__content"> <nav class="c-navbar__nav"> <ul class="c-navbar__nav c-navbar__nav--journal" role="menu" data-test="site-navigation"> <li class="c-navbar__item" role="menuitem"> <a class="c-navbar__link" data-track="click" data-track-category="Home" data-track-action="Clicked journal navigation link" href='/'>Home</a> </li> <li class="c-navbar__item" role="menuitem"> <a class="c-navbar__link" data-track="click" data-track-category="About" data-track-action="Clicked journal navigation link" href='/about'>About</a> </li> <li class="c-navbar__item" role="menuitem"> <a class="c-navbar__link c-navbar__link--is-shown" data-track="click" data-track-category="Articles" data-track-action="Clicked journal navigation link" href='/articles'>Articles</a> </li> <li class="c-navbar__item" role="menuitem"> <a class="c-navbar__link" data-track="click" data-track-category="Collections" data-track-action="Clicked journal navigation link" href='/articles/collections'>Collections</a> </li> <li class="c-navbar__item" role="menuitem"> <a class="c-navbar__link" data-track="click" data-track-category="Submission Guidelines" data-track-action="Clicked journal navigation link" href='/submission-guidelines'>Submission Guidelines</a> </li> <li class="c-navbar__item" role="menuitem" data-test="journal-header-submit-button"> <div class=""> <a class="u-button u-button--tertiary u-button--alt-colour-on-mobile" href="https://www.editorialmanager.com/idop/" data-track="click_submit_manuscript" data-track-action="manuscript submission" data-track-category="article" data-track-label="button in journal nav" data-track-context="journal header on article page" data-track-external data-test="submit-manuscript-button">Submit manuscript<svg class="u-ml-8" width="15" height="16" aria-hidden="true" focusable="false"><use xlink:href="#icon-submit-open"></use></svg></a> </div> </li> </ul> </nav> </div> </div> </div> <div class="c-journal-header__identity c-journal-header__identity--ocean-light-blue"> </div> </header> <div class="u-container u-mt-32 u-mb-32 u-clearfix" id="main-content" data-component="article-container"> <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body"> <div class="c-context-bar u-hide" data-test="context-bar" data-context-bar aria-hidden="true"> <div class="c-context-bar__container u-container" data-track-context="sticky banner"> <div class="c-context-bar__title"> Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under </div> <div class="c-pdf-container"> <div class="c-pdf-download u-clear-both"> <a href="//idpjournal.biomedcentral.com/counter/pdf/10.1186/s40249-016-0165-2.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="pdf-link" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external download> <span class="c-pdf-download__text">Download PDF</span> <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg> </a> </div> </div> </div> </div> <div class="c-pdf-button__container u-hide-at-lg js-context-bar-sticky-point-mobile"> <div class="c-pdf-container" data-track-context="article body"> <div class="c-pdf-download u-clear-both"> <a href="//idpjournal.biomedcentral.com/counter/pdf/10.1186/s40249-016-0165-2.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="pdf-link" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external download> <span class="c-pdf-download__text">Download PDF</span> <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg> </a> </div> </div> </div> <article lang="en"> <div class="c-article-header"> <ul class="c-article-identifiers" data-test="article-identifier"> <li class="c-article-identifiers__item" data-test="article-category">Research Article</li> <li class="c-article-identifiers__item"> <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a> </li> <li class="c-article-identifiers__item">Published: <time datetime="2016-07-06">06 July 2016</time></li> </ul> <h1 class="c-article-title" data-test="article-title" data-article-title="">Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under</h1> <ul class="c-article-author-list c-article-author-list--short" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Akintunde-Sowunmi-Aff1-Aff2" data-author-popup="auth-Akintunde-Sowunmi-Aff1-Aff2" data-author-search="Sowunmi, Akintunde" data-corresp-id="c1">Akintunde Sowunmi<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><sup class="u-js-hide"><a href="#Aff1">1</a>,<a href="#Aff2">2</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Kazeem-Akano-Aff1" data-author-popup="auth-Kazeem-Akano-Aff1" data-author-search="Akano, Kazeem">Kazeem Akano</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Adejumoke_I_-Ayede-Aff3" data-author-popup="auth-Adejumoke_I_-Ayede-Aff3" data-author-search="Ayede, Adejumoke I.">Adejumoke I. Ayede</a><sup class="u-js-hide"><a href="#Aff3">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Godwin-Ntadom-Aff4" data-author-popup="auth-Godwin-Ntadom-Aff4" data-author-search="Ntadom, Godwin">Godwin Ntadom</a><sup class="u-js-hide"><a href="#Aff4">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Elsie_O_-Adewoye-Aff5" data-author-popup="auth-Elsie_O_-Adewoye-Aff5" data-author-search="Adewoye, Elsie O.">Elsie O. Adewoye</a><sup class="u-js-hide"><a href="#Aff5">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Bayo-Fatunmbi-Aff6" data-author-popup="auth-Bayo-Fatunmbi-Aff6" data-author-search="Fatunmbi, Bayo">Bayo Fatunmbi</a><sup class="u-js-hide"><a href="#Aff6">6</a></sup> & </li><li class="c-article-author-list__show-more" aria-label="Show all 7 authors for this article" title="Show all 7 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Temitope-Aderoyeje-Aff7" data-author-popup="auth-Temitope-Aderoyeje-Aff7" data-author-search="Aderoyeje, Temitope">Temitope Aderoyeje</a><sup class="u-js-hide"><a href="#Aff7">7</a></sup> </li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button> <p class="c-article-info-details" data-container-section="info"> <a data-test="journal-link" href="/" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Infectious Diseases of Poverty</i></a> <b data-test="journal-volume"><span class="u-visually-hidden">volume</span> 5</b>, Article number: <span data-test="article-number">70</span> (<span data-test="article-publication-year">2016</span>) <a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a> </p> <div class="c-article-metrics-bar__wrapper u-clear-both"> <ul class="c-article-metrics-bar u-list-reset"> <li class=" c-article-metrics-bar__item" data-test="access-count"> <p class="c-article-metrics-bar__count">2181 <span class="c-article-metrics-bar__label">Accesses</span></p> </li> <li class="c-article-metrics-bar__item" data-test="citation-count"> <p class="c-article-metrics-bar__count">7 <span class="c-article-metrics-bar__label">Citations</span></p> </li> <li class="c-article-metrics-bar__item" data-test="altmetric-score"> <p class="c-article-metrics-bar__count">1 <span class="c-article-metrics-bar__label">Altmetric</span></p> </li> <li class="c-article-metrics-bar__item"> <p class="c-article-metrics-bar__details"><a href="/articles/10.1186/s40249-016-0165-2/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p> </li> </ul> </div> </div> <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Background</h3><p>Artemisinin-based combination therapies are recommended as first-line treatments for uncomplicated falciparum malaria, but there is little evaluation of their efficacy and effects on uncomplicated malaria-associated anaemia in children aged 2 years and under.</p><h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Methods</h3><p>Parasitological efficacy and effects on malaria-associated anaemia were evaluated in 250 malarious children aged 2 years and under, and efficacy was evaluated in 603 malarious children older than two but younger than 5 years of age following treatment with artesunate-amodiaquine (AA) or artemether-lumefantrine (AL). Kinetics of the disposition of parasitaemia following treatment were evaluated using a non-compartment model. Late-appearing anaemia (LAA) was diagnosed using the following criteria: clearance of parasitaemia, fever and other symptoms occurring within 7 days of starting treatment, adequate clinical and parasitological response on days 28–42, haematocrit (HCT) ≥ 30 % at 1 and/or 2 weeks, a fall in HCT to < 30 % occurring at 3–6 weeks, absence of concomitant illness at 1–6 weeks, and absence of asexual parasitaemia detected using both microscopy and polymerase chain reaction (PCR) at 1–6 weeks.</p><h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Results</h3><p>Overall, in children aged 2 years and under, the PCR-corrected parasitological efficacy was 97.2 % (95 % <i>CI</i> 92.8–101.6), which was similar for both treatments. In children older than 2 years, parasitological efficacy was also similar for both treatments, but parasite prevalence 1 day after treatment began was significantly higher, and fever and parasite clearance times were significantly faster in the AA-treated children compared with the AL-treated children. Declines in parasitaemia were monoexponential with an estimated elimination half-time of 1 h. Elimination half-times were similar for both treatments. In children aged 2 years and under who were anaemic at presentation, the mean anaemia recovery time was 12.1 days (95 % <i>CI</i> 10.6–13.6, <i>n</i> = 127), which was similar for both treatments. Relatively asymptomatic LAA occurred in 11 children (4.4 %) aged 2 years and under, the recovery from which was uneventful.</p><h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Conclusion</h3><p>This study showed that AA and AL are efficacious treatments for uncomplicated falciparum malaria in Nigerian children aged 2 years and under, and that AA clears parasitaemia and fever significantly faster than AL in children older than 2 years. Both treatments may cause a relatively asymptomatic LAA with uneventful recovery in a small proportion of children aged 2 years and under.</p><h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Trials registration</h3><p>Pan African Clinical Trial Registry PACTR201508001188143, 3 July 2015; PACTR201510001189370, 3 July 2015; PACTR201508001191898, 7 July 2015 and PACTR201508001193368, 8 July 2015 <a href="http://www.pactr.org">http://www.pactr.org</a>.</p></div></div></section> <section data-title="Multilingual abstracts"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Multilingual abstracts</h2><div class="c-article-section__content" id="Sec1-content"><p>Please see Additional file <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/10.1186/s40249-016-0165-2#MOESM1">1</a> for translations of the abstract into the five official working languages of the United Nations.</p></div></div></section><section data-title="Background"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Background</h2><div class="c-article-section__content" id="Sec2-content"><p>Artemisinin-based combination therapies (ACTs) have remained efficacious since their adoption as first-line treatments for uncomplicated <i>Plasmodium falciparum</i> malaria [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="World Health Organisation. World malaria report 2014. Geneva: WHO; 2014. 
 http://who.int/malaria/publications/world_malaria_report_2014/en/
 
 ." href="/articles/10.1186/s40249-016-0165-2#ref-CR1" id="ref-link-section-d92645107e579">1</a>]. In Nigeria, artemether-lumefantrine (AL) and artesunate-amodiaquine (AA) were adopted as first-line treatments in 2005 [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Federal Ministry of Health. National Antimalaria Treatment Guideline. Abuja, Nigeria. Federal Ministry of Health; 2005." href="/articles/10.1186/s40249-016-0165-2#ref-CR2" id="ref-link-section-d92645107e582">2</a>]. However, recent reports of artemisinin resistance in <i>P. falciparum</i> malaria [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="World Health Organization. Status Report on Artemisinin and ACT Resistance. Geneva: WHO; 2015. 
 http://www.who.int/malaria/publications/atoz/update-artemisinin-resistance-sep2015/en/
 
 ." href="/articles/10.1186/s40249-016-0165-2#ref-CR3" id="ref-link-section-d92645107e588">3</a>] in the Greater Mekong subregion [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Wongsrichanalai C, Meshnick S. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis. 2008;14:716–9." href="/articles/10.1186/s40249-016-0165-2#ref-CR4" id="ref-link-section-d92645107e592">4</a>–<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day N, White NJ, Anderson TMJ, Nosten F. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960–6." href="/articles/10.1186/s40249-016-0165-2#ref-CR9" id="ref-link-section-d92645107e595">9</a>], and its declining responsiveness reported in Kenya [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, Frühauf H, Schaub B, Pfeil J, Peshu J, Hanpithakpong W, Rippert A, Juma E, Tsofa B, Mosobo M, Lowe B, Oseir F, Fegan G, Lindegårdh N, Nzila A, Peshu N, Mackinnon M, Marsh K. Decline responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS ONE. 2011;6:26005." href="/articles/10.1186/s40249-016-0165-2#ref-CR10" id="ref-link-section-d92645107e598">10</a>] and Suriname [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Vreden SGS, Jitan JK, Bansie RD, Adhin MA. Evidence of an increased incidence of day 3 parasitaemia in Suriname: an indicator of the emerging resistance of Plasmodium falciparum to artemether. Mem Inst Oswaldo Cruz Rio de Janeiro. 2013;108:968–73." href="/articles/10.1186/s40249-016-0165-2#ref-CR11" id="ref-link-section-d92645107e601">11</a>], have made it imperative to monitor, on a continuous basis, the efficacy of ACTs for treating <i>P. falciparum</i> malaria globally.</p><p>Traditionally, in endemic areas, antimalarial efficacy assessments have been carried out in children younger than 5 years of age because of this age group’s relative lack of antimalarial immunity [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="World Health Organization. Chemotherapy of Malaria and Resistance to Antimalarials. Geneva: World Health Organization; 1973." href="/articles/10.1186/s40249-016-0165-2#ref-CR12" id="ref-link-section-d92645107e610">12</a>]. However, it is unclear if very young children (≤2 years old) differ in therapeutic responses from those older than two but younger than 5 years of age. Additionally, there has been little or no evaluation of the efficacy of these drug combinations in children with uncomplicated falciparum malaria who are aged 2 years and under. Such information is necessary as it may aid in the early detection of declining responsiveness of <i>P. falciparum</i> malaria infections to ACTs in children, as well as help guide appropriate responses.</p><p>In the present study, we analyzed the responsiveness of <i>P. falciparum</i> infections to AA and AL in the 10-year period since the adoption of these as first-line treatments for uncomplicated falciparum malaria in Nigeria. We compared the therapeutic responses to the two ACTs in children aged 2 years and under with children older than 2 years of age. In addition, we evaluated the recovery from malaria-associated anaemia and described late-appearing anaemia (LAA) in children aged 2 years and under.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec3-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec3">Methods</h2><div class="c-article-section__content" id="Sec3-content"><h3 class="c-article__sub-heading" id="Sec4">Study sites</h3><p>The study was conducted between October 2009 and November 2010 at the following sites in Nigeria: Agbani in Enugu State, Barkin Ladi in Plateau State, and Damboa in Borno State (the eastern flank of the study sites); Ijede in Lagos State and Makarfi in Kaduna State (the western flank of the study sites); and in Sabo quarters of Ibadan, Oyo State, located on the western flank between 2005 and 2015 (see Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s40249-016-0165-2#Fig1">1</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Fig. 1"><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/10.1186/s40249-016-0165-2/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40249-016-0165-2/MediaObjects/40249_2016_165_Fig1_HTML.gif?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40249-016-0165-2/MediaObjects/40249_2016_165_Fig1_HTML.gif" alt="figure 1" loading="lazy"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p>Study profile. AA, artesunate-amodiaquine; AL, artemether-lumefantrine, *follow-up was for 42 days, **follow-up was for 28 days, #number of children that completed follow-up period</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/10.1186/s40249-016-0165-2/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div> <p>In virtually all study locations, malaria is hyperendemic and transmission occurs all year round, however, it is more intense during the rainy season, which lasts from April to October. <i>P. falciparum</i> is the predominant species, accounting for over 98 % of all infections [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="World Health Organisation. World malaria report 2014. Geneva: WHO; 2014. 
 http://who.int/malaria/publications/world_malaria_report_2014/en/
 
 ." href="/articles/10.1186/s40249-016-0165-2#ref-CR1" id="ref-link-section-d92645107e661">1</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Salako LA, Ajayi FO, Sowunmi A, Walker O. Malaria in Nigeria: a revisit. Ann Trop Med Parasitol. 1990;84:435–45." href="/articles/10.1186/s40249-016-0165-2#ref-CR13" id="ref-link-section-d92645107e664">13</a>]. Children are more affected than adults and asymptomatic infections more often occur in older school children aged greater than 5 years and adults [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Salako LA, Ajayi FO, Sowunmi A, Walker O. Malaria in Nigeria: a revisit. Ann Trop Med Parasitol. 1990;84:435–45." href="/articles/10.1186/s40249-016-0165-2#ref-CR13" id="ref-link-section-d92645107e667">13</a>]. The details pertaining to the larger studies conducted have been reported elsewhere [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Sowunmi A, Gbotosho GO, Happi CT, Adedeji AA, Fehintola FA. Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulphalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. Am J Trop Med Hyg. 2007;77:235–41." href="/articles/10.1186/s40249-016-0165-2#ref-CR14" id="ref-link-section-d92645107e670">14</a>–<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, Agomo C, Ntadom G, Banjo O, Okuboyejo T, Ogunrinde G, Odey F, Aina O, Sofola T, Sowunmi A. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five year-old Nigerian children. Am J Trop Med Hyg. 2014;91:925–35." href="/articles/10.1186/s40249-016-0165-2#ref-CR20" id="ref-link-section-d92645107e674">20</a>].</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec5">Study procedure</h4><p>Specific study procedures have been described for each study conducted before [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Sowunmi A, Gbotosho GO, Happi CT, Adedeji AA, Fehintola FA. Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulphalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. Am J Trop Med Hyg. 2007;77:235–41." href="/articles/10.1186/s40249-016-0165-2#ref-CR14" id="ref-link-section-d92645107e684">14</a>–<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, Agomo C, Ntadom G, Banjo O, Okuboyejo T, Ogunrinde G, Odey F, Aina O, Sofola T, Sowunmi A. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five year-old Nigerian children. Am J Trop Med Hyg. 2014;91:925–35." href="/articles/10.1186/s40249-016-0165-2#ref-CR20" id="ref-link-section-d92645107e687">20</a>]. All enrolment procedures are the same at all sites. Patients were eligible for evaluation if they were: aged 6–24 months or 25–59 months, had symptoms compatible with acute uncomplicated <i>P. falciparum</i> malaria with a monoinfection ≥ 1 000 μL<sup>−1</sup> of blood, no history of antimalarial drug ingestion in the 2 weeks prior to enrolment, absence of severe malaria and obtained written informed consent from parents or guardians.</p><p>Enrolled patients were randomized and received AL or AA (co-formulated). Artemether-lumefantrine (Coartem®, Novartis, Basel, Switzerland) was administered according to body weight: patients weighing 5–14 kg received one tablet; those weighing 15–24 kg received two tablets at presentation (0 h), 8 h later, and at 24, 36, 48 and 60 h after the first dose. Each tablet of AL contained 20 mg of artemether and 120 mg of lumefantrine. Artesunate-amodiaquine (Coarsucam®, Sanofi Aventis, France) was also administered according to body weight: patients weighing from 4.5 to under 9 kg received one tablet of 25 mg/67.5 mg of a fixed-dose combination of artesunate/amodiaquine respectively, those weighing 9 to under 18 kg received one tablet of 50 mg/135 mg, and those weighing 18 to under 24 kg received one tablet of 100 mg/270 mg, daily for 3 days. Children older than 2 years were treated with AA or AL, as previously described [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, Agomo C, Ntadom G, Banjo O, Okuboyejo T, Ogunrinde G, Odey F, Aina O, Sofola T, Sowunmi A. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five year-old Nigerian children. Am J Trop Med Hyg. 2014;91:925–35." href="/articles/10.1186/s40249-016-0165-2#ref-CR20" id="ref-link-section-d92645107e698">20</a>].</p><p>All drugs were given orally. All doses of AA were given by direct observed therapy. The doses of AL at presentation (day 0, 0 h), and at 8, 24 and 48 h were administered by direct observed therapy. Doses of AL at 36 and 60 h were given by parents/guardians at home.</p><p>Thick and thin blood films were obtained from each child as soon as he/she came to the clinic, and the slides were carefully labeled with the patients’ codes and air-dried before being stained. The slides were examined by light microscopy under an oil-immersion objective lens at 1000× magnification by two independent assessors who did not know the drug regimen of the patients. A senior member of the study team reviewed the slides if there was any disagreement between the two microscopists. In addition, the slides of every fourth child were reviewed by the senior member. Parasitaemia, asexual or sexual, was estimated by counting the asexual and sexual parasites relative to 500 leukocytes, or 500 asexual or sexual forms, whichever occurred first, in the thick films. Using this figure, the parasite density was calculated assuming a leukocyte count of 6 000 μL<sup>−1</sup> of blood. A slide was considered parasite negative if no asexual or sexual parasite was detected after examination of 200 microscopic fields. A clinical and parasitological evaluation was done on days 1–3 and on days 7, 14, 21 and 28 at all study sites, except in Ibadan where additional follow-up was done on days 35 and 42.</p><p>Cure rates on day 28 were adjusted based on the polymerase chain reaction (PCR) genotyping results of patients’ recurrent parasitaemia paired samples 7 days after starting treatment, as previously described [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, Agomo C, Ntadom G, Banjo O, Okuboyejo T, Ogunrinde G, Odey F, Aina O, Sofola T, Sowunmi A. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five year-old Nigerian children. Am J Trop Med Hyg. 2014;91:925–35." href="/articles/10.1186/s40249-016-0165-2#ref-CR20" id="ref-link-section-d92645107e713">20</a>]. An asexual parasite reduction ratio (PRR) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="White NJ. Assessment of the pharmacodynamics properties of antimalarial drugs in vivo. Antimicrob Agent Chemother. 1997;41:1413–22." href="/articles/10.1186/s40249-016-0165-2#ref-CR21" id="ref-link-section-d92645107e716">21</a>] was defined as the ratio of day 0/day 2 parasitaemia (and for convenience, referred to as PRR<sub>D2</sub>): that is, <span class="mathjax-tex">\( PR{R}_{D2}=\left.\frac{Parasitaemia\ on\ day\ 0}{Parasitaemia\ on\ day\ 2}\right] \)</span>. The asexual PRR on day 1 (PRR<sub>D1</sub>) was defined as the ratio of day 0/day 1 parasitaemia: that is, <span class="mathjax-tex">\( PR{R}_{D1}=\left.\frac{Parasitaemia\ on\ day\ 0}{Parasitaemia\ on\ day\ 1}\right] \)</span>.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec6">Kinetics of the disposition of parasitaemia following treatment</h4><p>In 20 children aged 2 years and under, enrolled between 2008 and 2015 at the Ibadan study site, clinical and parasitological evaluations were done at the following times: at 0, 1, 2, 4, 6, 8 and 24 h, and on days 2–7, 14, 21, 28, 35 and 42. The kinetics of the time-course of the parasitaemia was estimated using a non-compartmental model, as previously described [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Gbotosho GO, Sowunmi A, Happi CT, Okuboyejo TM. Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments. Am J Trop Med Hyg. 2011;84:936–43." href="/articles/10.1186/s40249-016-0165-2#ref-CR17" id="ref-link-section-d92645107e898">17</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Sowunmi A, Falade AG, Adedeji AA, Ayede AI, Fateye BA, Sowunmi CO, Oduola AMJ. Comparative Plasmodium falciparum kinetics during treatment with amodiaquine and chloroquine in children. Clin Drug Investig. 2001;21:371–81." href="/articles/10.1186/s40249-016-0165-2#ref-CR22" id="ref-link-section-d92645107e901">22</a>].</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec7">Haematological evaluation</h4><p>Capillary blood collected before and during follow-up was used to measure haematocrit (HCT) using a microhaematocrit tube and microcentrifuge (Hawksley, Lancing, UK). Anaemia was defined as HCT < 30 %, and was classified as either mild, moderate or severe if HCT was 21–29, 15–20 or < 15 %, respectively. Anaemia recovery time (AnRT) (in anaemic patients) was defined as the time elapsed from drug administration to getting a HCT value ≥ 30 % [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Gbotosho GO, Sowunmi A, Okuboyejo TM, Happi CT, Folarin OO, Michael SO, Adewoye EO. Therapeutic efficacy and effect of artemether-lumefantrine and artesunate-amodiaquine cofomulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in southwest Nigeria. Am J Trop Med Hyg. 2011;84:813–9." href="/articles/10.1186/s40249-016-0165-2#ref-CR18" id="ref-link-section-d92645107e913">18</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, Agomo C, Ntadom G, Banjo O, Okuboyejo T, Ogunrinde G, Odey F, Aina O, Sofola T, Sowunmi A. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five year-old Nigerian children. Am J Trop Med Hyg. 2014;91:925–35." href="/articles/10.1186/s40249-016-0165-2#ref-CR20" id="ref-link-section-d92645107e916">20</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Sowunmi A, Balogun ST, Gbotosho GO, Happi CT. Effects of amodiaquine, artesunate, and artesunate-amodiaquine of Plasmodium falciparum malaria-associated anaemia in children. Acta Tropic. 2009;109:55–60." href="/articles/10.1186/s40249-016-0165-2#ref-CR23" id="ref-link-section-d92645107e919">23</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Sowunmi A, Akano K, Ayede AI, Ntadom G, Aderoyeje T, Adewoye EO, Fatunmbi, B. Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children. BMC Infect Dis. 2015;15:454." href="/articles/10.1186/s40249-016-0165-2#ref-CR24" id="ref-link-section-d92645107e922">24</a>].</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec8">Diagnosis of LAA after administering ACTs</h4><p>In children aged 2 years and under, a diagnosis of LAA was made if the following criteria were met following the initiation of ACTs: clearance of parasitaemia, fever and other symptoms occurring within seven days of starting treatment, adequate clinical and parasitological response (ACPR) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization; 2003." href="/articles/10.1186/s40249-016-0165-2#ref-CR25" id="ref-link-section-d92645107e933">25</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="World Health Organization. Methods for surveillance of antimalarial drug efficacy. World Health Organization: Geneva; 2009." href="/articles/10.1186/s40249-016-0165-2#ref-CR26" id="ref-link-section-d92645107e936">26</a>] on days 28–42, HCT ≥ 30 % at 1 and/or 2 weeks, a fall in HCT to < 30 % occurring at 3–6 weeks, absence of concomitant illness at 1–6 weeks, and absence of asexual parasitaemia detected using both microscopy and PCR at 1–6 weeks (Sowunmi et al., 2015, unpublished, submitted for publication).</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec9">Statistical analysis</h4><p>Data were analyzed using the Epi Info™ version 6 software (Centers for Disease Control and Prevention, Atlanta, GA, USA) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Anon. Epi Info Version 6. A Word Processing Data Base and Statistics Program for Public Health on IBM-compatible Microcomputers. Atlanta: Centers for Disease Control and Prevention; 1994." href="/articles/10.1186/s40249-016-0165-2#ref-CR27" id="ref-link-section-d92645107e947">27</a>] and the statistical program SPSS for Windows version 20.0 (SPSS Inc., Chicago IL, USA) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Anon. SPSS for Windows Release 20.0 (standard version). Chicago: SPSS Inc; 2011." href="/articles/10.1186/s40249-016-0165-2#ref-CR28" id="ref-link-section-d92645107e950">28</a>]. Variables considered in the analysis were related to the densities of <i>P. falciparum</i> asexual and sexual forms. Proportions were compared by calculating <i>χ</i> <sup>2</sup> using Yates’s correction, Fisher’s exact or Cochran-Mantel-Haenszel tests. Normally distributed, continuous data were compared using the Student’s <i>t</i>-test and analysis of variance (ANOVA). Data not conforming to a normal distribution were compared using the Mann-Whitney <i>U</i> test and the Kruskal-Wallis H test (or by Wilcoxon rank sum test). The relationship between two continuous variables was assessed using the Spearman’s rank correlation coefficient. The cumulative risk of parasite reappearance was calculated by survival using the Kaplan-Meier method. <i>P</i>-values of < 0.05 were considered statistically significant. Data were double-entered serially using patients’ codes and were only analyzed at the end of the study.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec10">Ethical clearance</h4><p>The study protocol was approved by the Ministry of Health, Ibadan and the National Health Research Ethics Committee, Abuja, Nigeria. Written informed consents were obtained from parents/guardians of the children.</p></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec11-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec11">Results</h2><div class="c-article-section__content" id="Sec11-content"><h3 class="c-article__sub-heading" id="Sec12">Patient characteristics at enrolment</h3><p>During the study period, a total of 911 children aged younger than 5 years from five geographical areas of Nigeria who had parasitaemia were enrolled and treated with AA or AL. Of these, 272 (30 %) were aged 2 years and under (see Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s40249-016-0165-2#Fig1">1</a>) and of those, 250 were evaluated in this study. The characteristics of the children at enrolment in each study site and for each year of study are shown in Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/10.1186/s40249-016-0165-2#Tab1">1</a>.</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption class="c-article-table__figcaption"><b id="Tab1" data-test="table-caption">Table 1 Baseline characteristics of ≤ 2-year old malarious children at enrolment according to year and site of study</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/10.1186/s40249-016-0165-2/tables/1" aria-label="Full size table 1"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div> <p>Children enrolled in Ibadan between 2005 and 2010 but not between 2011 and 2015, were significantly older and had a significantly higher body temperature and enrolment parasitaemia compared with children enrolled at the other study sites. Children enrolled in Barkin Ladi had a significantly higher HCT at enrolment. In children aged 2 years and under, anaemia at presentation was more significantly common in children older than 1 year of age compared with children aged 1 year and under (103/185 versus 25/65; <i>P</i> <0.05).</p><h3 class="c-article__sub-heading" id="Sec13">Therapeutic responses</h3><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec14">Children ≤ 2 years old</h4><p>In children aged 2 years and under, the overall PCR-corrected ACPR on day 28 was 97.2 % (95 % <i>CI</i> 92.8–101.6). Overall, for both treatments and for all study sites, the PCR-uncorrected ACPR on day 28 was 234/250 (94 %) and the PCR-corrected ACPR on day 28 was 234/247 (95 %) (see Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/10.1186/s40249-016-0165-2#Tab2">2</a>).</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-2"><figure><figcaption class="c-article-table__figcaption"><b id="Tab2" data-test="table-caption">Table 2 Overall efficacy of artesunate-amodiaquine or artemether-lumefantrine in ≥2 years old malarious children according to study sites</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/10.1186/s40249-016-0165-2/tables/2" aria-label="Full size table 2"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div> <p>Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/10.1186/s40249-016-0165-2#Tab3">3</a> shows the therapeutic responses to AA and AL for each study site. For AA, the overall PCR-corrected ACPR on day 28 was 99.3 % (95 % <i>CI</i> 97.6–101) at all sites. The PCR-uncorrected ACPR on day 28 was 112/120 (93 %) and the PCR-corrected ACPR on day 28 was 112/116 (97 %). The PCR-corrected ACPR was similar at all sites. For AL, the overall PCR-corrected ACPR on day 28 was 96.9 % (95 % <i>CI</i> 91.5–102.3) at all sites. The PCR-uncorrected ACPR on day 28 was 122/130 (94 %) and the PCR-corrected ACPR on day 28 was 122/127 (96 %). The PCR-corrected ACPR was similar at all sites. Overall, the PCR-corrected ACPR on day 28 was similar for both treatments (99.3 % versus 96.9 % for AA and AL, respectively; <i>P</i> >0.05).</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-3"><figure><figcaption class="c-article-table__figcaption"><b id="Tab3" data-test="table-caption">Table 3 Efficacy of artesunate-amodiaquine or artemether-lumefantrine in ≥2 years old malarious children according to study site and year of enrolment</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/10.1186/s40249-016-0165-2/tables/3" aria-label="Full size table 3"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div> <p>No child had early treatment failure, however, late parasitological failure (LPF) occurred in 16 children, who were all enrolled between 2005 and 2010. There was no significant difference in the proportions of children with LPF in the two treatment groups (8/120 children treated with AA versus 8/130 children treated with AL, <i>P</i> >0.05). The proportion of children with LPF was also similar in infants and non-infants, and was not related to their anaemia status at presentation (4/65 versus 12/185 in infants and non-infants, respectively, <i>P</i> >0.05; and 10/127 versus 6/123 in anaemic and non-anaemic children, respectively, <i>P</i> >0.05).</p><p>Recrudescence occurred in nine children (six from Agbani and three from Barkin Ladi). Recrudescence occurred in four children treated with AA and five children treated with AL. Overall, mean time to recrudescence was 21.8 ± 5.5 days (range 14–28) and was similar in children treated with AA and AL (22.8 ± 6.7 days [range 14–28] versus 21 ± 4.9 days [range 14–28]; <i>P</i> = 0.66). The probabilities of the reappearance of asexual parasitaemia after treatment were similar between AA and AL (log-rank statistic = 0.006, <i>P</i> = 0.94, see Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s40249-016-0165-2#Fig2">2a</a>). The probabilities of reappearance of asexual parasitaemia after treatment with both drugs were similar in infants and non-infants (log-rank statistic = 0.03, <i>P</i> = 0.86, see Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s40249-016-0165-2#Fig2">2b</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Fig. 2"><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/10.1186/s40249-016-0165-2/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40249-016-0165-2/MediaObjects/40249_2016_165_Fig2_HTML.gif?as=webp"><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40249-016-0165-2/MediaObjects/40249_2016_165_Fig2_HTML.gif" alt="figure 2" loading="lazy"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p>Kaplan-Meier survival estimates of asexual parasitaemia (<b>a</b>) after treatment of ≤ 2 years old children with AA (<i>blue line</i>) or AL (<i>green line</i>; log-rank statistic = 0.006; <i>P</i> = 0.94) and (<b>b</b>) in infants (<i>green line</i>) and non-infants (<i>blue line</i>) treated with AA or AL (log-rank statistic = 0.03; <i>P</i> = 0.86). AA, artesunate-amodiaquine; AL, artemether-lumefantrine</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/10.1186/s40249-016-0165-2/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div> <p>Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/10.1186/s40249-016-0165-2#Tab4">4</a> shows that other measures of therapeutic responses were similar in children treated with AA and AL. Only three children (two on AA and one on AL) exhibited parasitaemia on day 3.</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-4"><figure><figcaption class="c-article-table__figcaption"><b id="Tab4" data-test="table-caption">Table 4 Other measures of treatment outcomes in children ≤ 2 treated with artesunate-amodiaquine or artemether-lumefantrine</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/10.1186/s40249-016-0165-2/tables/4" aria-label="Full size table 4"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div> <h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec15">Children ≤ 2 years old at the Ibadan study site</h4><p>Overall, the therapeutic responses of 61 children aged 2 years and under were evaluated during the 10-year period since AA and AL were introduced as first-line treatments for malaria in Nigeria (47 children from 2005 to 2010 and 14 children from 2011 to 2015). Of the 61 children, 26 were treated with AA and 35 with AL. Because of the small number of patients, therapeutic responses over the years were merged for both treatments. Baseline parameters at enrolment were similar for both AA and AL. Mean age (1.6 ± 0.5 years versus 1.6 ± 0.4 years, <i>P</i> = 0.43) and geometric mean parasitaemia (28,143 μL<sup>−1</sup> [1614–128,976] versus 29,629 μL<sup>−1</sup> [4938–304,500]; <i>P</i> = 0.68) were similar for the AA and AL treatment groups, respectively. Therapeutic responses were also similar for the two treatments: ACPR on day 28 (26/26 versus 35/35), geometric mean PRR (1.9 × 10<sup>4</sup> [range 2.2 × 10<sup>2</sup>–1.3 × 10<sup>5</sup>] versus 4.9 × 10<sup>3</sup> [range 1.7 × 10<sup>0</sup>–2.9 × 10<sup>5</sup>]; and 2.8 × 10<sup>4</sup> [range 1.6 × 10<sup>3</sup>– 1.3 × 10<sup>5</sup>] versus 2.8 × 10<sup>4</sup> [range 1.9 × 10<sup>3</sup>–3.0 × 10<sup>5</sup>] one and 2 days after treatment began, respectively) and fever clearance time (FCT) (1.2 ± 0.1 standard error of mean, SEM [range 1–4, <i>n</i> = 22] versus 1.5 ± 0.2 SEM [1–7, <i>n</i> = 26]). The parasite clearance time (PCT) was significantly shorter for children treated with AA than for those treated with AL (1.1 ± 0.3 [range 1–2] versus 1.3 ± 0.5 [range 1–3]).</p><p>During the two study periods (2005–2010 and 2011–2015), the proportions of children with ACPR on day 28 (47/47 versus 14/14), parasite prevalence 1 day after treatment began (8/47 versus 3/14), PRRs (9.0 × 10<sup>3</sup> [range 1.7 × 10<sup>0</sup>–2.9 × 10<sup>5</sup>] versus 7.4 × 10<sup>3</sup> [range 1.2 × 10<sup>2</sup>–1.1 × 10<sup>5</sup>], and 3.1 × 10<sup>4</sup> [range 1.6 × 10<sup>3</sup>–3.0 × 10<sup>5</sup>] versus 2.0 × 10<sup>4</sup> [range 1.9 × 10<sup>3</sup>–1.1 × 10<sup>5</sup>] 1 and 2 days after treatment began, respectively), FCTs (1.4 ± 0.2 SEM [range 1–7, <i>n</i> = 39] versus 1.3 ± 0.3 SEM [1–4, <i>n</i> = 9]), and PCTs (1.2 ± 0.4 [range 1–2] versus 1.3 ± 0.6 [range 1–3]) were similar.</p><h3 class="c-article__sub-heading" id="Sec16">Therapeutic responses according to treatment and age groups</h3><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec17">Comparison of therapeutic responses in children ≤ 2 and > 2– < 5 years</h4><p>Comparing all children treated with AA or AL showed that the PRRs one and 2 days after treatment began were significantly higher in children older than 2 years but younger than 5 years of age than in children aged 2 years and under (1.1 × 10<sup>3</sup> [range 3.2 × 10<sup>−1</sup>–2.1 × 10<sup>6</sup>] versus 5.5 × 10<sup>2</sup> [range 1.1 × 10<sup>−1</sup>–2.9 × 10<sup>5</sup>], <i>P</i> = 0.01; and 1.9 × 10<sup>4</sup> [range 1.7 × 10<sup>1</sup>–2.1 × 10<sup>6</sup>] versus 1.1 × 10<sup>4</sup> [range 1.9 × 10<sup>1</sup>–3.0 × 10<sup>5</sup>]; <i>P</i> < 0.0001; respectively). Fever clearance time and AnRT were significantly lower in children aged older than 2 years but younger than 5 years compared with children aged 2 years and under (1.1 days [95 % <i>CI</i> 1.1–1.2, <i>n</i> = 179] versus 1.3 days [95 % <i>CI</i> 1.2–1.4, <i>n</i> = 450], <i>P</i> = 0.02; and 10.7 days [95 % <i>CI</i> 9.6–11.7, <i>n</i> = 179] versus 12.8 days [95 % <i>CI</i> 11.1–14.4, <i>n</i> = 450], <i>P</i> <0.03; respectively). Other measures of therapeutic responses, for example, the PCR-corrected ACRP on day 28 (234/244 [96.3 %] versus 559/589 [94.9 %], <i>P</i> > 0.05); parasite prevalence 1 day after treatment began (126/250 [50 %] versus 278/603 [46 %], <i>P</i> > 0.05); and parasite positivity rate on day 3 (3/250 versus 7/603, <i>P</i> > 0.05), respectively, were similar in children aged 2 years and under and those older than 2 years but younger than 5 years.</p><p> <b>AA:</b> In children younger than 1 year old (<i>n</i> = 29) and those 1 year old and above (<i>n</i> = 91) who were treated with AA, no significant differences were observed in the therapeutic responses to the drug. In children aged 2 years and under (<i>n</i> = 120) and those older than 2 years but younger than 5 years (<i>n</i> = 315) who were treated with AA, PRRs 1 and 2 days after treatment began were significantly higher. The FCT was significantly lower in children older than 2 years but younger than 5 years of age compared with children aged 2 years and under (see Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/10.1186/s40249-016-0165-2#Tab5">5</a>).</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-5"><figure><figcaption class="c-article-table__figcaption"><b id="Tab5" data-test="table-caption">Table 5 Therapeutic outcomes based on age group in children treated with artesunate-amodiaquine</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/10.1186/s40249-016-0165-2/tables/5" aria-label="Full size table 5"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div> <p> <b>AL:</b> In children younger than 1 year (<i>n</i> = 46) and those 1 year or above (<i>n</i> = 84) who were treated with AL, the parasite prevalence 1 day after treatment began and PCTs were significantly lower in children younger than 1 year compared with children 1 year or older. In children aged 2 years and under (<i>n</i> = 130) and those older than 2 years but younger than 5 years (<i>n</i> = 288) who were treated with AL, the PRR 2 days after treatment began was significantly lower in children older than 2 years but younger than 5 years compared with children aged 2 years and under (see Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/10.1186/s40249-016-0165-2#Tab6">6</a>).</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-6"><figure><figcaption class="c-article-table__figcaption"><b id="Tab6" data-test="table-caption">Table 6 Therapeutic outcomes based on age group in children treated with artemether-lumefantrine</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/10.1186/s40249-016-0165-2/tables/6" aria-label="Full size table 6"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div> <h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec18">Comparison of therapeutic responses in children aged > 2– < 5 years</h4><p>Three hundred and fifteen children and 288 children older than 2 years of age were treated with AA and AL, respectively. The parasite prevalence 1 day after treatment began (124/315 [39 %] children versus 154/288 [53 %] children, <i>P <</i> 0.05), FCT (1.1 ± 0.3 days [95 % <i>CI</i> 1–1.1 <i>n</i> = 234] versus 1.2 ± 0.7 days [95 % <i>CI</i> 1.1–1.3, <i>n</i> = 222]; <i>P</i> = 0.002), and PCT (1.4 ± 0.6 days [95 % <i>CI</i> 1.4–1.5] versus 1.6 ± 0.6 days [95 % <i>CI</i> 1.5–1.7]; <i>P <</i> 0.05) were significantly lower in children treated with AA compared with those treated with AL. The PRR 1 day after treatment began was significantly higher in children treated with AA compared with those treated with AL (1.9 × 10<sup>3</sup> [range 3.2 × 10<sup>−1</sup>–1.1 × 10<sup>6</sup>] versus 5.6 × 10<sup>2</sup> [range 9.5 × 10<sup>−1</sup>–2.1 × 10<sup>6</sup>]; <i>P <</i> 0.05). However, the PCR-corrected ACPR on day 28 (294/310 [95 %] versus 265/279 [95 %] for AA and AL, respectively; <i>P</i> >0.05) and the AnRT (10.4 days [95 % <i>CI</i> 9–11.8] versus 11 days [95 % <i>CI</i> 9.4–12.6] for AA and AL, respectively; <i>P</i> >0.05) were similar for the two treatment groups.</p><h3 class="c-article__sub-heading" id="Sec19">Kinetics of the disposition of parasitaemia</h3><p>In children aged 2 years and under, the kinetics of the disposition of parasitaemia were evaluated in 20 children with the following demographic and clinical characteristics: mean age = 1.6 years (range 0.6–2), male/female ratio 13:7, mean duration of illness = 2.3 days (range 1–4), mean body temperature = 38.1 °C (range 36.6–39.9 °C, no. with > 37.4 °C = 12), mean HCT = 28 % (range 20–38, no. with < 30 % = 12), geometric mean asexual parasitaemia of 48,580 μL<sup>−1</sup> (range 3625–288,461; no. with > 100,000 μL<sup>−1</sup> = 5; no. with > 250,000 μL<sup>−1</sup> = 1), mean FCT = 1.1 days (range 1–2), mean PCT = 1.2 days (range 1–3), and mean AnRT 13.5 days (range 1–28).</p><p>Overall, a monoexponential decline of parasitaemia was observed, with an estimated mean elimination half-time (t<sub>½el</sub>) of 1 h (95 % <i>CI</i> 0.9–1.1) (see Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s40249-016-0165-2#Fig3">3a</a>). The estimated mean t<sub>½el</sub> values were similar for AA (1 h, 95 % <i>CI</i> 0.9–1.2)- and AL (0.9 h, 95 % <i>CI</i> 0.9–1.7)- treated children (<i>P</i> >0.05) (see Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s40249-016-0165-2#Fig3">3b</a>). In children aged 1 year old and under (<i>n</i> = 3) and those older than 1 year (<i>n</i> = 17), the estimated mean elimination half-times were 0.9 h (95 % <i>CI</i> 0.2–1.5) and 1 h (95 % <i>CI</i> 0.9–1.6), respectively; they were similar (<i>P</i> >0.05) (see Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/10.1186/s40249-016-0165-2#Fig3">3c</a>). Estimated mean elimination half-times were also similar in children with enrolment parasitaemia ≥ 100 000 μL<sup>−1</sup> and those with < 100 000 μL<sup>−1</sup> (1 h [95 % <i>CI</i> 0.6–1.4, <i>n</i> = 5] versus 1 h [95 % <i>CI</i> 0.9–1.1, <i>n</i> = 15]; <i>P</i> >0.05, respectively) and in anaemic and non-anaemic children at presentation (1 h [95 % <i>CI</i> 0.8–1.1, <i>n</i> = 11] versus 1 h [95 % <i>CI</i> 0.7–1.2, <i>n</i> = 9]; <i>P</i> >0.05, respectively).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Fig. 3"><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/10.1186/s40249-016-0165-2/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40249-016-0165-2/MediaObjects/40249_2016_165_Fig3_HTML.gif?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40249-016-0165-2/MediaObjects/40249_2016_165_Fig3_HTML.gif" alt="figure 3" loading="lazy"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p>Semilog plots of parasitaemia versus time (<b>a</b>) in all, (<b>b</b>) in AA (<i>blue</i>) and AL (<i>green</i>)-treated children and (<b>c</b>) in ≤ 1-year olds (<i>blue</i>) and > 1-year olds (<i>green</i>). [AA, artesunate-amodiaquine; AL, artemether-lumefantrine]</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/10.1186/s40249-016-0165-2/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div> <h3 class="c-article__sub-heading" id="Sec20">Relationship between elimination half-time of parasitaemia and PCT</h3><p>The relationship between the elimination half-time of parasitaemia and PCT in the same patients was evaluated in 20 children aged 2 years old and under. The mean elimination half-time of parasitaemia was 1 h (95 % <i>CI</i> 0.9–1.1) and PCT was 1.1 day (95 % <i>CI</i> 1–1.2). A significantly positive correlation was observed between elimination half-time of parasitaemia and PCT in the same patients (<i>r</i> = 0.64, <i>P</i> <0.05), however, no correlation was observed between elimination half-time of parasitaemia and PRRs 1 or 2 days after treatment began (<i>r</i> = 0.42, <i>P</i> >0.05 and <i>r</i> = 0.21, <i>P</i> >0.05, respectively).</p><h3 class="c-article__sub-heading" id="Sec21">Adverse events</h3><p>Adverse events were carefully monitored at the Ibadan study site. Thirteen of the 61 children aged 2 years and under (8/26 on AA and 5/35 on AL) reported at least one adverse event within 1 week of starting treatment. There was no significant difference in the proportions of children reporting adverse events between the two treatment groups (<i>P</i> >0.05). Overall, fever (<i>n</i> = 7) and cough (<i>n</i> = 7) were the most frequently reported adverse events in children treated with AA and AL. Abdominal pain (<i>n</i> = 1) and weakness (<i>n</i> = 1) were the least reported adverse events; they were reported only in the group treated with AA. Almost all the reported adverse events occurred in children aged older than 1 year.</p><p>Fifty-five out of 241 children older than two but younger than 5 years (40/128 on AA and 15/113 on AL) reported at least one adverse event within 1 week of starting treatment. There was a significant difference in the proportions of children reporting adverse events between the two treatment groups (<i>P</i> <0.05). Overall, there was no significant difference in the reported adverse events in those aged 2 years and under and those older than two but younger than 5 years old (<i>P</i> >0.05).</p><p>Overall, fever (<i>n</i> = 29) and cough (<i>n</i> = 23) were the most frequently reported adverse events in children treated with AA and AL. Weakness (<i>n</i> = 4) was the least reported adverse event.</p><h3 class="c-article__sub-heading" id="Sec22">Recovery from anaemia</h3><p>In children aged 2 years and under, anaemia was present at enrolment in 127 children, and was mild, moderate or severe in 112 (88 %), 14 (11 %) and 1 (1 %) children, respectively. All but 13 children with anaemia at presentation recovered from their anaemia. Of the 13 children who did not recover from their anaemia, 10 and three children had mild and moderate anaemia, respectively. In the 114 children who recovered from anaemia, the mean AnRT was 12.1 days (95 % <i>CI</i> 10.6–13.6) and was similar for the two treatment groups (12.2 days [95 % <i>CI</i> 9.9–14.4, <i>n</i> = 60] versus 12.1 days [95 % <i>CI</i> 10.0–14.2, <i>n</i> = 54] in AA- and AL-treated children, respectively [<i>P</i> >0.05]). The AnRT was also similar in children aged 1 year and under and those aged 1 year and over (13.1 days [95 % <i>CI</i> 9.7–16.5, <i>n</i> = 23] versus 11.9 days [95 % <i>CI</i> 10.1–13.6, <i>n</i> = 91]; <i>P</i> >0.05). Overall, the mean AnRT was significantly longer in children with high enrolment parasitaemia (≥100,000 μL<sup>−1</sup>) compared with those with low enrolment parasitaemia (<100,000 μL<sup>−1</sup>) (19.1 days [95 % <i>CI</i> 10.5–27.7, <i>n</i> = 7] versus 11.7 days [95 % <i>CI</i> 10.1–13.2, <i>n</i> = 107]; <i>P</i> = 0.02). A significantly positive correlation was observed between AnRT and enrolment parasitaemia (<i>r</i> = 0.24, <i>P</i> <0.05, <i>n</i> = 114), but there was no correlation between AnRT and age (<i>r</i> = 0.15, <i>P</i> <0.05, <i>n</i> = 114) or HCT at presentation (<i>r</i> = 0.11, <i>P</i> >0.05, <i>n</i> = 114) in the same patients.</p><h3 class="c-article__sub-heading" id="Sec23">Late-appearing anaemia following treatment</h3><p>Eleven children aged 2 years and under (4.4 %) had LAA (see Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/10.1186/s40249-016-0165-2#Tab7">7</a>). The mean elapsed time from the start of treatment to appearance of late anaemia was 24.2 days (range 21–28 days). None of the 11 children reported a symptom at the time of LAA, but one child had a body temperature of 39.5 °C at the time of appearance of late anaemia. Three out of five children treated with AA had > 11 mg/kg total dose of artesunate. Five children did not recover from their LAA; these children were followed up for 28 days.</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-7"><figure><figcaption class="c-article-table__figcaption"><b id="Tab7" data-test="table-caption">Table 7 Features of ≤ 2 years old children who developed anaemia after day 14</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/10.1186/s40249-016-0165-2/tables/7" aria-label="Full size table 7"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div> </div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec24-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec24">Discussion</h2><div class="c-article-section__content" id="Sec24-content"><p>In this study, both AA and AL were proved to be effective treatments for uncomplicated falciparum malaria, as evidenced by a PCR-corrected parasitological efficacy of over 96 %. Both treatments were similar in their therapeutic efficacy. In children older than 2 years of age, both treatments rapidly reduce parasitaemia and fever compared with children aged 2 years and below. These findings suggest that therapeutic responses to both ACTs were not uniform across the age range of below 5 years and may be influenced by age. Children older than 2 years may possess some relative degree of immunity compared with very young children.</p><p>Among the children older than 2 years, AA was superior in clearing parasitaemia and fever. This would suggest that the superior efficacy of AA over AL in clearing parasitaemia and fever in children younger than 5 years of age in this endemic area [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Gbotosho GO, Sowunmi A, Happi CT, Okuboyejo TM. Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments. Am J Trop Med Hyg. 2011;84:936–43." href="/articles/10.1186/s40249-016-0165-2#ref-CR17" id="ref-link-section-d92645107e7749">17</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Gbotosho GO, Sowunmi A, Okuboyejo TM, Happi CT, Folarin OO, Michael SO, Adewoye EO. Therapeutic efficacy and effect of artemether-lumefantrine and artesunate-amodiaquine cofomulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in southwest Nigeria. Am J Trop Med Hyg. 2011;84:813–9." href="/articles/10.1186/s40249-016-0165-2#ref-CR18" id="ref-link-section-d92645107e7752">18</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, Agomo C, Ntadom G, Banjo O, Okuboyejo T, Ogunrinde G, Odey F, Aina O, Sofola T, Sowunmi A. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five year-old Nigerian children. Am J Trop Med Hyg. 2014;91:925–35." href="/articles/10.1186/s40249-016-0165-2#ref-CR20" id="ref-link-section-d92645107e7755">20</a>] can, to a large extent, be attributable to the effects of AA on parasitaemia and fever clearance in children older than 2 years. Children older than 2 years form the bulk of the children under 5 years of age that are usually included in therapeutic efficacy studies in endemic areas. The small number of patients (3/250 children ≤ 2 years and 7/603 children >2– < 5) who exhibited parasite positivity on day 3 indicates that there is no evidence for slow clearance of parasitaemia in very young and older children in this endemic area. The low parasite positivity on day 3 is in contradiction to the situation in the Greater Mekong subregion, where parasite positivity on day 3 is high in children treated with artemisinin [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="World Health Organization. Status Report on Artemisinin and ACT Resistance. Geneva: WHO; 2015. 
 http://www.who.int/malaria/publications/atoz/update-artemisinin-resistance-sep2015/en/
 
 ." href="/articles/10.1186/s40249-016-0165-2#ref-CR3" id="ref-link-section-d92645107e7758">3</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewka K, Marion B, Brockman A, Anderson T, McGready R, Phaiphun L, Stephane P, van Vugt M, Hutagalung R, Lwin KM, Phyo AP, Piyanuch P, Imwong M, Pukrittayakamee S, Singhasivanon P, White NJ, Nosten F. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One. 2009;4:e511." href="/articles/10.1186/s40249-016-0165-2#ref-CR7" id="ref-link-section-d92645107e7761">7</a>].</p><p>The monoexponential declines of parasitaemia indicated that the disposition of parasitaemia following treatment with both ACTs is a first-order process. The parasitaemia elimination half-time of 1 h provides a baseline for which future changes in parasite population in vivo and in vitro susceptibility profile in very young children from this endemic area may be measured or compared. It is noteworthy that the elimination half-time of parasitaemia of 1 h is considerably lower than the 5.5 h reported in areas in the Greater Mekong subregion where resistance to artemisinin has emerged [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day N, White NJ, Anderson TMJ, Nosten F. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960–6." href="/articles/10.1186/s40249-016-0165-2#ref-CR9" id="ref-link-section-d92645107e7767">9</a>].</p><p>Reported adverse events following treatment were few, and were similar for the two ACTs. The relative lack of reported adverse events in very young children can be attributed to their inability to name them. In children older than 2 years, the reported adverse events were significantly more frequent in those children treated with AA compared with those treated with AL. This finding is similar to a recent study conducted in older patients, where reported adverse events were more frequent in those treated with AA compared with AL [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Schramm B, Valch P, Baudin C, Mazinda CS, Smith R, Pinoges I, Sundaygar T, Zolia YM, Jones JJ, Comte E, Bruneel A, Branger M, Jullien V, Cam G, Kiechel J-R, Ashley EA, Guérin PJ. Tolerability and safety of artesunate-amodiaquine and artemether-lumefatrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trial in Nimba County, Liberia. Malar J. 2013;12:250." href="/articles/10.1186/s40249-016-0165-2#ref-CR29" id="ref-link-section-d92645107e7773">29</a>].</p><p>Virtually all children who were anaemic at presentation recovered from their anaemia within 2 weeks of starting treatment, a time similar to that previously reported in a cohort study of children aged younger than 5 years [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, Agomo C, Ntadom G, Banjo O, Okuboyejo T, Ogunrinde G, Odey F, Aina O, Sofola T, Sowunmi A. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five year-old Nigerian children. Am J Trop Med Hyg. 2014;91:925–35." href="/articles/10.1186/s40249-016-0165-2#ref-CR20" id="ref-link-section-d92645107e7780">20</a>]. An interesting finding was the relatively asymptomatic nature of LAA, which occurred in 4 % of very young children. It has been reported that symptomatic delayed haemolytic anaemia can occur following intravenous artesunate treatment of severe malaria in immunological naïve patients [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Zoller T, Junghanss T, Kapaun A, Gjørup I, Richter J, Hugo-Persson M, Mørch K, Foroutan B, Suttorp N, Yürek S, Flick H. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis. 2011;17:771–7." href="/articles/10.1186/s40249-016-0165-2#ref-CR30" id="ref-link-section-d92645107e7783">30</a>–<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="World Health Organization. WHO information note on delayed haemolytic anaemia following treatment with artesunate. Geneva: WHO; 2013." href="/articles/10.1186/s40249-016-0165-2#ref-CR32" id="ref-link-section-d92645107e7786">32</a>] and in African children [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Rolling T, Agbenyega T, Issifou S, Adegnika AA, Sylverken J, Spahlinger D, Ansong D, Löhr SJ, Burchard GD, May J, Mordmuller B, Krishna S, Kremsner PG, Cramer JP. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria – a double-center prospective study. J Infect Dis. 2014;209:1921–8." href="/articles/10.1186/s40249-016-0165-2#ref-CR33" id="ref-link-section-d92645107e7789">33</a>], and is attributable to a delayed destruction of once-parasitized red blood cells from which the parasites have been removed by ‘pitting’ during passage through the spleen [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Jauréguiberry S, Ndour PA, Roussel C, Ader F, Safeukui I, Nguyen M, Biligui S, Ciceron L, Mouri O, Kendjo E, Vray M, Angoulvant A, Mayaux J, Haldar K, Mazier D, Danis M, Caumes E, Thellier M, Buffet P. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood. 2014;124:167–75." href="/articles/10.1186/s40249-016-0165-2#ref-CR34" id="ref-link-section-d92645107e7792">34</a>]. The relatively asymptomatic nature of and the paucity of signs during LAA may be responsible for the failure to recognize LAA as a ‘saving’ effect of ACTs due to rapid clearance of parasitaemia and conservation of HCT. The children who did not recover from their LAA were followed up for 28 days. It is now necessary to follow up children treated with ACTs for 42 days in order to detect and ensure that children with LAA recover from it. Thus, LAA may have practical implications in endemic areas where ACTs have become first-line treatments for uncomplicated malaria and where anaemia is a significant contributor to morbidity.</p><p>There limitations of the present study, in particular with late-appearing anaemia. These include non-characterization of the haemolytic nature of the late-appearing anaemia and non-evaluation of the contributions of background causes of anaemia in this endemic area to the late-appearing anaemia.</p></div></div></section><section data-title="Conclusion"><div class="c-article-section" id="Sec25-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec25">Conclusion</h2><div class="c-article-section__content" id="Sec25-content"><p>This study found that AA and AL are both efficacious treatments for uncomplicated falciparum malaria in Nigerian children aged 2 years but therapeutic responses to the two ACTs are not uniform across the age band 6–59 months. Both treatments may cause a relatively asymptomatic LAA with uneventful recovery in a small proportion of very young children.</p></div></div></section><section data-title="Abbreviations"><div class="c-article-section" id="Sec26-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec26">Abbreviations</h2><div class="c-article-section__content" id="Sec26-content"><p>AA, artesunate-amodiaquine; ACPR, adequate clinical and parasitological response; ACT, artemisinin-based combination therapy; AL, artemether-lumefantrine; ANOVA, analysis of variance; AnRT, anaemia recovery time; FCT, fever clearance time; HCT, haematocrit; LAA, late-appearing anaemia; LPF, late parasitological failure; PCR, polymerase chain reaction; PCT, parasite clearance time; PPR, parasite reduction ratio; PRR<sub>D1</sub>, parasite reduction ratio 1 day after treatment began; PRR<sub>D2</sub>, parasite reduction ratio 2 days after treatment began; SEM, standard error of mean; t<sub>½</sub>, half-time</p></div></div></section> <div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">World Health Organisation. World malaria report 2014. Geneva: WHO; 2014. <a href="http://who.int/malaria/publications/world_malaria_report_2014/en/" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="http://who.int/malaria/publications/world_malaria_report_2014/en/">http://who.int/malaria/publications/world_malaria_report_2014/en/</a>.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&title=World%20malaria%20report%202014&publication_year=2014"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Federal Ministry of Health. National Antimalaria Treatment Guideline. Abuja, Nigeria. Federal Ministry of Health; 2005.</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">World Health Organization. Status Report on Artemisinin and ACT Resistance. Geneva: WHO; 2015. <a href="http://www.who.int/malaria/publications/atoz/update-artemisinin-resistance-sep2015/en/" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="http://www.who.int/malaria/publications/atoz/update-artemisinin-resistance-sep2015/en/">http://www.who.int/malaria/publications/atoz/update-artemisinin-resistance-sep2015/en/</a>.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&title=Status%20Report%20on%20Artemisinin%20and%20ACT%20Resistance&publication_year=2015"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Wongsrichanalai C, Meshnick S. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis. 2008;14:716–9.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3201/eid1405.071601" data-track-item_id="10.3201/eid1405.071601" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3201%2Feid1405.071601" aria-label="Article reference 4" data-doi="10.3201/eid1405.071601">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18439351" aria-label="PubMed reference 4">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600243" aria-label="PubMed Central reference 4">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&title=Declining%20artesunate-mefloquine%20efficacy%20against%20falciparum%20malaria%20on%20the%20Cambodia-Thailand%20border&journal=Emerg%20Infect%20Dis&doi=10.3201%2Feid1405.071601&volume=14&pages=716-719&publication_year=2008&author=Wongsrichanalai%2CC&author=Meshnick%2CS"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin resistance in western Cambodia. N Engl J Med. 2008;359:2619–20.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMc0805011" data-track-item_id="10.1056/NEJMc0805011" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMc0805011" aria-label="Article reference 5" data-doi="10.1056/NEJMc0805011">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXhsV2ms7rM" aria-label="CAS reference 5">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19064625" aria-label="PubMed reference 5">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&title=Evidence%20of%20artemisinin%20resistance%20in%20western%20Cambodia&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMc0805011&volume=359&pages=2619-2620&publication_year=2008&author=Noedl%2CH&author=Se%2CY&author=Schaecher%2CK&author=Smith%2CBL&author=Socheat%2CD&author=Fukuda%2CMM"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, Rutvisuttinunt W, Bethell D, Surasri S, Fukuda MM, Socheat D, Cham TL. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010;51:e82–9.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1086/657120" data-track-item_id="10.1086/657120" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1086%2F657120" aria-label="Article reference 6" data-doi="10.1086/657120">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21028985" aria-label="PubMed reference 6">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&title=Artemisinin%20resistance%20in%20Cambodia%3A%20a%20clinical%20trial%20designed%20to%20address%20an%20emerging%20problem%20in%20Southeast%20Asia&journal=Clin%20Infect%20Dis&doi=10.1086%2F657120&volume=51&pages=e82-e89&publication_year=2010&author=Noedl%2CH&author=Se%2CY&author=Sriwichai%2CS&author=Schaecher%2CK&author=Teja-Isavadharm%2CP&author=Smith%2CB&author=Rutvisuttinunt%2CW&author=Bethell%2CD&author=Surasri%2CS&author=Fukuda%2CMM&author=Socheat%2CD&author=Cham%2CTL"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewka K, Marion B, Brockman A, Anderson T, McGready R, Phaiphun L, Stephane P, van Vugt M, Hutagalung R, Lwin KM, Phyo AP, Piyanuch P, Imwong M, Pukrittayakamee S, Singhasivanon P, White NJ, Nosten F. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One. 2009;4:e511.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0004551" data-track-item_id="10.1371/journal.pone.0004551" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0004551" aria-label="Article reference 7" data-doi="10.1371/journal.pone.0004551">Article</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&title=Changes%20in%20the%20treatment%20responses%20to%20artesunate-mefloquine%20on%20the%20northwestern%20border%20of%20Thailand%20during%2013%C2%A0years%20of%20continuous%20deployment&journal=PLoS%20One&doi=10.1371%2Fjournal.pone.0004551&volume=4&publication_year=2009&author=Carrara%2CVI&author=Zwang%2CJ&author=Ashley%2CEA&author=Price%2CRN&author=Stepniewka%2CK&author=Marion%2CB&author=Brockman%2CA&author=Anderson%2CT&author=McGready%2CR&author=Phaiphun%2CL&author=Stephane%2CP&author=Vugt%2CM&author=Hutagalung%2CR&author=Lwin%2CKM&author=Phyo%2CAP&author=Piyanuch%2CP&author=Imwong%2CM&author=Pukrittayakamee%2CS&author=Singhasivanon%2CP&author=White%2CNJ&author=Nosten%2CF"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Lim P, Alker A, Khim N, Shah N, Incardona S, Doung S, Yi P, Bouth D, Boucher C, Mercereau P, Meshnick S, Wongsrichanalai C, Fandeur T, Bras J, Ringwald P, Ariey F. <i>Pfmdr1</i> copy number and artemisinin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J. 2009;8:11.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/1475-2875-8-11" data-track-item_id="10.1186/1475-2875-8-11" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/1475-2875-8-11" aria-label="Article reference 8" data-doi="10.1186/1475-2875-8-11">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19138391" aria-label="PubMed reference 8">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627910" aria-label="PubMed Central reference 8">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&title=Pfmdr1%20copy%20number%20and%20artemisinin%20derivatives%20combination%20therapy%20failure%20in%20falciparum%20malaria%20in%20Cambodia&journal=Malar%20J&doi=10.1186%2F1475-2875-8-11&volume=8&publication_year=2009&author=Lim%2CP&author=Alker%2CA&author=Khim%2CN&author=Shah%2CN&author=Incardona%2CS&author=Doung%2CS&author=Yi%2CP&author=Bouth%2CD&author=Boucher%2CC&author=Mercereau%2CP&author=Meshnick%2CS&author=Wongsrichanalai%2CC&author=Fandeur%2CT&author=Bras%2CJ&author=Ringwald%2CP&author=Ariey%2CF"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day N, White NJ, Anderson TMJ, Nosten F. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960–6.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(12)60484-X" data-track-item_id="10.1016/S0140-6736(12)60484-X" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2812%2960484-X" aria-label="Article reference 9" data-doi="10.1016/S0140-6736(12)60484-X">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22484134" aria-label="PubMed reference 9">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525980" aria-label="PubMed Central reference 9">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&title=Emergence%20of%20artemisinin-resistant%20malaria%20on%20the%20western%20border%20of%20Thailand%3A%20a%20longitudinal%20study&journal=Lancet&doi=10.1016%2FS0140-6736%2812%2960484-X&volume=379&pages=1960-1966&publication_year=2012&author=Phyo%2CAP&author=Nkhoma%2CS&author=Stepniewska%2CK&author=Ashley%2CEA&author=Nair%2CS&author=McGready%2CR&author=Moo%2CC&author=Al-Saai%2CS&author=Dondorp%2CAM&author=Lwin%2CKM&author=Singhasivanon%2CP&author=Day%2CN&author=White%2CNJ&author=Anderson%2CTMJ&author=Nosten%2CF"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, Frühauf H, Schaub B, Pfeil J, Peshu J, Hanpithakpong W, Rippert A, Juma E, Tsofa B, Mosobo M, Lowe B, Oseir F, Fegan G, Lindegårdh N, Nzila A, Peshu N, Mackinnon M, Marsh K. Decline responsiveness of <i>Plasmodium falciparum</i> infections to artemisinin-based combination treatments on the Kenyan coast. PLoS ONE. 2011;6:26005.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0026005" data-track-item_id="10.1371/journal.pone.0026005" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0026005" aria-label="Article reference 10" data-doi="10.1371/journal.pone.0026005">Article</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&title=Decline%20responsiveness%20of%20Plasmodium%20falciparum%20infections%20to%20artemisinin-based%20combination%20treatments%20on%20the%20Kenyan%20coast&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0026005&volume=6&publication_year=2011&author=Borrmann%2CS&author=Sasi%2CP&author=Mwai%2CL&author=Bashraheil%2CM&author=Abdallah%2CA&author=Muriithi%2CS&author=Fr%C3%BChauf%2CH&author=Schaub%2CB&author=Pfeil%2CJ&author=Peshu%2CJ&author=Hanpithakpong%2CW&author=Rippert%2CA&author=Juma%2CE&author=Tsofa%2CB&author=Mosobo%2CM&author=Lowe%2CB&author=Oseir%2CF&author=Fegan%2CG&author=Lindeg%C3%A5rdh%2CN&author=Nzila%2CA&author=Peshu%2CN&author=Mackinnon%2CM&author=Marsh%2CK"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Vreden SGS, Jitan JK, Bansie RD, Adhin MA. Evidence of an increased incidence of day 3 parasitaemia in Suriname: an indicator of the emerging resistance of <i>Plasmodium falciparum</i> to artemether. Mem Inst Oswaldo Cruz Rio de Janeiro. 2013;108:968–73.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1590/0074-0276130167" data-track-item_id="10.1590/0074-0276130167" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1590%2F0074-0276130167" aria-label="Article reference 11" data-doi="10.1590/0074-0276130167">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXhtFyiu7jN" aria-label="CAS reference 11">CAS</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&title=Evidence%20of%20an%20increased%20incidence%20of%20day%203%20parasitaemia%20in%20Suriname%3A%20an%20indicator%20of%20the%20emerging%20resistance%20of%20Plasmodium%20falciparum%20to%20artemether&journal=Mem%20Inst%20Oswaldo%20Cruz%20Rio%20de%20Janeiro&doi=10.1590%2F0074-0276130167&volume=108&pages=968-973&publication_year=2013&author=Vreden%2CSGS&author=Jitan%2CJK&author=Bansie%2CRD&author=Adhin%2CMA"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">World Health Organization. Chemotherapy of Malaria and Resistance to Antimalarials. Geneva: World Health Organization; 1973.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&title=Chemotherapy%20of%20Malaria%20and%20Resistance%20to%20Antimalarials&publication_year=1973"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Salako LA, Ajayi FO, Sowunmi A, Walker O. Malaria in Nigeria: a revisit. Ann Trop Med Parasitol. 1990;84:435–45.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DyaK3M%2Fns1Knsw%3D%3D" aria-label="CAS reference 13">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=2256767" aria-label="PubMed reference 13">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&title=Malaria%20in%20Nigeria%3A%20a%20revisit&journal=Ann%20Trop%20Med%20Parasitol&volume=84&pages=435-445&publication_year=1990&author=Salako%2CLA&author=Ajayi%2CFO&author=Sowunmi%2CA&author=Walker%2CO"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Sowunmi A, Gbotosho GO, Happi CT, Adedeji AA, Fehintola FA. Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulphalene-pyrimethamine on gametocyte carriage in children with uncomplicated <i>Plasmodium falciparum</i> malaria in southwestern Nigeria. Am J Trop Med Hyg. 2007;77:235–41.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2sXhtVWqtb7J" aria-label="CAS reference 14">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17690392" aria-label="PubMed reference 14">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&title=Therapeutic%20efficacy%20and%20effects%20of%20artemether-lumefantrine%20and%20amodiaquine-sulphalene-pyrimethamine%20on%20gametocyte%20carriage%20in%20children%20with%20uncomplicated%20Plasmodium%20falciparum%20malaria%20in%20southwestern%20Nigeria&journal=Am%20J%20Trop%20Med%20Hyg&volume=77&pages=235-241&publication_year=2007&author=Sowunmi%2CA&author=Gbotosho%2CGO&author=Happi%2CCT&author=Adedeji%2CAA&author=Fehintola%2CFA"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Sowunmi A, Gbotosho GO, Happi CT, Folarin O, Okuboyejo T, Michael O, Fatunmbi B. Use of area under the curve to evaluate the effects of antimalarial drugs on malaria-associated anaemia after treatment. Am J Therap. 2011;118:1190–7.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&title=Use%20of%20area%20under%20the%20curve%20to%20evaluate%20the%20effects%20of%20antimalarial%20drugs%20on%20malaria-associated%20anaemia%20after%20treatment&journal=Am%20J%20Therap&volume=118&pages=1190-1197&publication_year=2011&author=Sowunmi%2CA&author=Gbotosho%2CGO&author=Happi%2CCT&author=Folarin%2CO&author=Okuboyejo%2CT&author=Michael%2CO&author=Fatunmbi%2CB"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Sowunmi A, Okuboyejo TM, Gbotosho GO, Happi CT. Early changes in <i>Plasmodium falciparum</i> asexual and sexual populations in children with acute infections following treatment with artemisinin-based combination drugs. Mal Chemother Ctrl Elim. 2012;1:235498. doi:<a href="https://doi.org/10.4303/mcce/235498" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.4303/mcce/235498">10.4303/mcce/235498</a>.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&title=Early%20changes%20in%20Plasmodium%20falciparum%20asexual%20and%20sexual%20populations%20in%20children%20with%20acute%20infections%20following%20treatment%20with%20artemisinin-based%20combination%20drugs&journal=Mal%20Chemother%20Ctrl%20Elim&doi=10.4303%2Fmcce%2F235498&volume=1&publication_year=2012&author=Sowunmi%2CA&author=Okuboyejo%2CTM&author=Gbotosho%2CGO&author=Happi%2CCT"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Gbotosho GO, Sowunmi A, Happi CT, Okuboyejo TM. Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments. Am J Trop Med Hyg. 2011;84:936–43.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4269/ajtmh.2011.10-0722" data-track-item_id="10.4269/ajtmh.2011.10-0722" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4269%2Fajtmh.2011.10-0722" aria-label="Article reference 17" data-doi="10.4269/ajtmh.2011.10-0722">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21633031" aria-label="PubMed reference 17">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110368" aria-label="PubMed Central reference 17">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&title=Therapeutic%20efficacies%20of%20artemisinin-based%20combination%20therapies%20in%20Nigerian%20children%20with%20uncomplicated%20falciparum%20malaria%20during%20five%20years%20of%20adoption%20as%20first-line%20treatments&journal=Am%20J%20Trop%20Med%20Hyg&doi=10.4269%2Fajtmh.2011.10-0722&volume=84&pages=936-943&publication_year=2011&author=Gbotosho%2CGO&author=Sowunmi%2CA&author=Happi%2CCT&author=Okuboyejo%2CTM"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Gbotosho GO, Sowunmi A, Okuboyejo TM, Happi CT, Folarin OO, Michael SO, Adewoye EO. Therapeutic efficacy and effect of artemether-lumefantrine and artesunate-amodiaquine cofomulated or copackaged on malaria-associated anemia in children with uncomplicated <i>Plasmodium falciparum</i> malaria in southwest Nigeria. Am J Trop Med Hyg. 2011;84:813–9.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4269/ajtmh.2011.10-0582" data-track-item_id="10.4269/ajtmh.2011.10-0582" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4269%2Fajtmh.2011.10-0582" aria-label="Article reference 18" data-doi="10.4269/ajtmh.2011.10-0582">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXns1Cisb8%3D" aria-label="CAS reference 18">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21540395" aria-label="PubMed reference 18">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083753" aria-label="PubMed Central reference 18">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&title=Therapeutic%20efficacy%20and%20effect%20of%20artemether-lumefantrine%20and%20artesunate-amodiaquine%20cofomulated%20or%20copackaged%20on%20malaria-associated%20anemia%20in%20children%20with%20uncomplicated%20Plasmodium%20falciparum%20malaria%20in%20southwest%20Nigeria&journal=Am%20J%20Trop%20Med%20Hyg&doi=10.4269%2Fajtmh.2011.10-0582&volume=84&pages=813-819&publication_year=2011&author=Gbotosho%2CGO&author=Sowunmi%2CA&author=Okuboyejo%2CTM&author=Happi%2CCT&author=Folarin%2COO&author=Michael%2CSO&author=Adewoye%2CEO"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Michael OS, Gbotosho GO, Folarin OA, Okuboyejo T, Sowunmi A, Oduola AMJ, Happi CT. Early variations in <i>Plasmodium falciparum</i> dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance. Malar J. 2010;9:335.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/1475-2875-9-335" data-track-item_id="10.1186/1475-2875-9-335" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/1475-2875-9-335" aria-label="Article reference 19" data-doi="10.1186/1475-2875-9-335">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3cXhsFejsrzJ" aria-label="CAS reference 19">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21092220" aria-label="PubMed reference 19">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152768" aria-label="PubMed Central reference 19">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&title=Early%20variations%20in%20Plasmodium%20falciparum%20dynamics%20in%20Nigerian%20children%20after%20treatment%20with%20two%20artemisinin-based%20combinations%3A%20implications%20on%20delayed%20parasite%20clearance&journal=Malar%20J&doi=10.1186%2F1475-2875-9-335&volume=9&publication_year=2010&author=Michael%2COS&author=Gbotosho%2CGO&author=Folarin%2COA&author=Okuboyejo%2CT&author=Sowunmi%2CA&author=Oduola%2CAMJ&author=Happi%2CCT"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, Agomo C, Ntadom G, Banjo O, Okuboyejo T, Ogunrinde G, Odey F, Aina O, Sofola T, Sowunmi A. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five year-old Nigerian children. Am J Trop Med Hyg. 2014;91:925–35.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4269/ajtmh.13-0248" data-track-item_id="10.4269/ajtmh.13-0248" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4269%2Fajtmh.13-0248" aria-label="Article reference 20" data-doi="10.4269/ajtmh.13-0248">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXitVyhsLzM" aria-label="CAS reference 20">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25246693" aria-label="PubMed reference 20">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228889" aria-label="PubMed Central reference 20">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&title=Efficacy%20of%20artemisinin-based%20combination%20treatments%20of%20uncomplicated%20falciparum%20malaria%20in%20under-five%20year-old%20Nigerian%20children&journal=Am%20J%20Trop%20Med%20Hyg&doi=10.4269%2Fajtmh.13-0248&volume=91&pages=925-935&publication_year=2014&author=Oguche%2CS&author=Okafor%2CHU&author=Watila%2CI&author=Meremikwu%2CM&author=Agomo%2CP&author=Ogala%2CW&author=Agomo%2CC&author=Ntadom%2CG&author=Banjo%2CO&author=Okuboyejo%2CT&author=Ogunrinde%2CG&author=Odey%2CF&author=Aina%2CO&author=Sofola%2CT&author=Sowunmi%2CA"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">White NJ. Assessment of the pharmacodynamics properties of antimalarial drugs in vivo. Antimicrob Agent Chemother. 1997;41:1413–22.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK2sXktlyrtb4%3D" aria-label="CAS reference 21">CAS</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&title=Assessment%20of%20the%20pharmacodynamics%20properties%20of%20antimalarial%20drugs%20in%20vivo&journal=Antimicrob%20Agent%20Chemother&volume=41&pages=1413-1422&publication_year=1997&author=White%2CNJ"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Sowunmi A, Falade AG, Adedeji AA, Ayede AI, Fateye BA, Sowunmi CO, Oduola AMJ. Comparative <i>Plasmodium falciparum</i> kinetics during treatment with amodiaquine and chloroquine in children. Clin Drug Investig. 2001;21:371–81.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.2165/00044011-200121050-00007" data-track-item_id="10.2165/00044011-200121050-00007" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.2165%2F00044011-200121050-00007" aria-label="Article reference 22" data-doi="10.2165/00044011-200121050-00007">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD3MXksVOjurc%3D" aria-label="CAS reference 22">CAS</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&title=Comparative%20Plasmodium%20falciparum%20kinetics%20during%20treatment%20with%20amodiaquine%20and%20chloroquine%20in%20children&journal=Clin%20Drug%20Investig&doi=10.2165%2F00044011-200121050-00007&volume=21&pages=371-381&publication_year=2001&author=Sowunmi%2CA&author=Falade%2CAG&author=Adedeji%2CAA&author=Ayede%2CAI&author=Fateye%2CBA&author=Sowunmi%2CCO&author=Oduola%2CAMJ"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Sowunmi A, Balogun ST, Gbotosho GO, Happi CT. Effects of amodiaquine, artesunate, and artesunate-amodiaquine of <i>Plasmodium falciparum</i> malaria-associated anaemia in children. Acta Tropic. 2009;109:55–60.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.actatropica.2008.09.022" data-track-item_id="10.1016/j.actatropica.2008.09.022" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.actatropica.2008.09.022" aria-label="Article reference 23" data-doi="10.1016/j.actatropica.2008.09.022">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXhsVertb%2FM" aria-label="CAS reference 23">CAS</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&title=Effects%20of%20amodiaquine%2C%20artesunate%2C%20and%20artesunate-amodiaquine%20of%20Plasmodium%20falciparum%20malaria-associated%20anaemia%20in%20children&journal=Acta%20Tropic&doi=10.1016%2Fj.actatropica.2008.09.022&volume=109&pages=55-60&publication_year=2009&author=Sowunmi%2CA&author=Balogun%2CST&author=Gbotosho%2CGO&author=Happi%2CCT"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Sowunmi A, Akano K, Ayede AI, Ntadom G, Aderoyeje T, Adewoye EO, Fatunmbi, B. Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children. BMC Infect Dis. 2015;15:454.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s12879-015-1219-y" data-track-item_id="10.1186/s12879-015-1219-y" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s12879-015-1219-y" aria-label="Article reference 24" data-doi="10.1186/s12879-015-1219-y">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26502714" aria-label="PubMed reference 24">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620624" aria-label="PubMed Central reference 24">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&title=Temporal%20changes%20in%20haematocrit%20following%20artemisinin-based%20combination%20treatments%20of%20uncomplicated%20falciparum%20malaria%20in%20children&journal=BMC%20Infect%20Dis&doi=10.1186%2Fs12879-015-1219-y&volume=15&publication_year=2015&author=Sowunmi%2CA&author=Akano%2CK&author=Ayede%2CAI&author=Ntadom%2CG&author=Aderoyeje%2CT&author=Adewoye%2CEO&author=Fatunmbi%2CB"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization; 2003.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&title=Assessment%20and%20monitoring%20of%20antimalarial%20drug%20efficacy%20for%20the%20treatment%20of%20uncomplicated%20falciparum%20malaria&publication_year=2003"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">World Health Organization. Methods for surveillance of antimalarial drug efficacy. World Health Organization: Geneva; 2009.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&title=Methods%20for%20surveillance%20of%20antimalarial%20drug%20efficacy&publication_year=2009"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Anon. Epi Info Version 6. A Word Processing Data Base and Statistics Program for Public Health on IBM-compatible Microcomputers. Atlanta: Centers for Disease Control and Prevention; 1994.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&title=Epi%20Info%20Version%206.%20A%20Word%20Processing%20Data%20Base%20and%20Statistics%20Program%20for%20Public%20Health%20on%20IBM-compatible%20Microcomputers&publication_year=1994"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">Anon. SPSS for Windows Release 20.0 (standard version). Chicago: SPSS Inc; 2011.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&title=SPSS%20for%20Windows%20Release%2020.0%20%28standard%20version%29&publication_year=2011"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Schramm B, Valch P, Baudin C, Mazinda CS, Smith R, Pinoges I, Sundaygar T, Zolia YM, Jones JJ, Comte E, Bruneel A, Branger M, Jullien V, Cam G, Kiechel J-R, Ashley EA, Guérin PJ. Tolerability and safety of artesunate-amodiaquine and artemether-lumefatrine fixed dose combinations for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria: two open-label, randomized trial in Nimba County, Liberia. Malar J. 2013;12:250.</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Zoller T, Junghanss T, Kapaun A, Gjørup I, Richter J, Hugo-Persson M, Mørch K, Foroutan B, Suttorp N, Yürek S, Flick H. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis. 2011;17:771–7.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3201/eid1705.101229" data-track-item_id="10.3201/eid1705.101229" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3201%2Feid1705.101229" aria-label="Article reference 30" data-doi="10.3201/eid1705.101229">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21529383" aria-label="PubMed reference 30">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321768" aria-label="PubMed Central reference 30">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&title=Intravenous%20artesunate%20for%20severe%20malaria%20in%20travelers%2C%20Europe&journal=Emerg%20Infect%20Dis&doi=10.3201%2Feid1705.101229&volume=17&pages=771-777&publication_year=2011&author=Zoller%2CT&author=Junghanss%2CT&author=Kapaun%2CA&author=Gj%C3%B8rup%2CI&author=Richter%2CJ&author=Hugo-Persson%2CM&author=M%C3%B8rch%2CK&author=Foroutan%2CB&author=Suttorp%2CN&author=Y%C3%BCrek%2CS&author=Flick%2CH"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Kreeftmeijer-Vetger AR, Genderen PJ, Visser LG, Bierman WFW, Clerinx J, van Veldehuizen CKW, de Vries PJ. Treatment outcome of intravenous artesunate in patients with severe malaria in Netherlands and Belgium. Malar J. 2012;11:102.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/1475-2875-11-102" data-track-item_id="10.1186/1475-2875-11-102" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/1475-2875-11-102" aria-label="Article reference 31" data-doi="10.1186/1475-2875-11-102">Article</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&title=Treatment%20outcome%20of%20intravenous%20artesunate%20in%20patients%20with%20severe%20malaria%20in%20Netherlands%20and%20Belgium&journal=Malar%20J&doi=10.1186%2F1475-2875-11-102&volume=11&publication_year=2012&author=Kreeftmeijer-Vetger%2CAR&author=Genderen%2CPJ&author=Visser%2CLG&author=Bierman%2CWFW&author=Clerinx%2CJ&author=Veldehuizen%2CCKW&author=Vries%2CPJ"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">World Health Organization. WHO information note on delayed haemolytic anaemia following treatment with artesunate. Geneva: WHO; 2013.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&title=WHO%20information%20note%20on%20delayed%20haemolytic%20anaemia%20following%20treatment%20with%20artesunate&publication_year=2013"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Rolling T, Agbenyega T, Issifou S, Adegnika AA, Sylverken J, Spahlinger D, Ansong D, Löhr SJ, Burchard GD, May J, Mordmuller B, Krishna S, Kremsner PG, Cramer JP. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria – a double-center prospective study. J Infect Dis. 2014;209:1921–8.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/infdis/jit841" data-track-item_id="10.1093/infdis/jit841" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Finfdis%2Fjit841" aria-label="Article reference 33" data-doi="10.1093/infdis/jit841">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXptVCgsbY%3D" aria-label="CAS reference 33">CAS</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24376273" aria-label="PubMed reference 33">PubMed</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&title=Delayed%20hemolysis%20after%20treatment%20with%20parenteral%20artesunate%20in%20African%20children%20with%20severe%20malaria%20%E2%80%93%20a%20double-center%20prospective%20study&journal=J%20Infect%20Dis&doi=10.1093%2Finfdis%2Fjit841&volume=209&pages=1921-1928&publication_year=2014&author=Rolling%2CT&author=Agbenyega%2CT&author=Issifou%2CS&author=Adegnika%2CAA&author=Sylverken%2CJ&author=Spahlinger%2CD&author=Ansong%2CD&author=L%C3%B6hr%2CSJ&author=Burchard%2CGD&author=May%2CJ&author=Mordmuller%2CB&author=Krishna%2CS&author=Kremsner%2CPG&author=Cramer%2CJP"> Google Scholar</a> </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Jauréguiberry S, Ndour PA, Roussel C, Ader F, Safeukui I, Nguyen M, Biligui S, Ciceron L, Mouri O, Kendjo E, Vray M, Angoulvant A, Mayaux J, Haldar K, Mazier D, Danis M, Caumes E, Thellier M, Buffet P. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood. 2014;124:167–75.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2014-02-555953" data-track-item_id="10.1182/blood-2014-02-555953" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2014-02-555953" aria-label="Article reference 34" data-doi="10.1182/blood-2014-02-555953">Article</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24859359" aria-label="PubMed reference 34">PubMed</a> <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093678" aria-label="PubMed Central reference 34">PubMed Central</a> <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&title=Postartesunate%20delayed%20hemolysis%20is%20a%20predictable%20event%20related%20to%20the%20lifesaving%20effect%20of%20artemisinins&journal=Blood&doi=10.1182%2Fblood-2014-02-555953&volume=124&pages=167-175&publication_year=2014&author=Jaur%C3%A9guiberry%2CS&author=Ndour%2CPA&author=Roussel%2CC&author=Ader%2CF&author=Safeukui%2CI&author=Nguyen%2CM&author=Biligui%2CS&author=Ciceron%2CL&author=Mouri%2CO&author=Kendjo%2CE&author=Vray%2CM&author=Angoulvant%2CA&author=Mayaux%2CJ&author=Haldar%2CK&author=Mazier%2CD&author=Danis%2CM&author=Caumes%2CE&author=Thellier%2CM&author=Buffet%2CP"> Google Scholar</a> </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1186/s40249-016-0165-2?format=refman&flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>We thank Prof. Christian Happi and Dr. Onikepe Folarin for performing the parasite genotyping for this study over the years. We specially thank Drs. Ismaila Watila and Philip Agomo, and Professors Henrietta U. Okafor, William Ogala and Martin Meremikwu for collecting the data and their permission to use the data pertaining to children enrolled in the therapeutic efficacy study at five of the six sentinel sites in Nigeria. The efficacy studies from which the data were derived were supported by a Swiss Pharma Nigeria PLC Grant given to AS, and by World Bank Malaria Booster Project and the Global Fund for Malaria to Federal Ministry of Health, Abuja, Nigeria through Drug Therapeutic Efficacy Testing in Nigeria.</p> <h3 class="c-article__sub-heading" id="FPar1">Authors’ contributions</h3> <p>AS led the design, conducted the data analysis and prepared the paper. KA, AIA, GN, EOA, BF and TA participated in the data collection and analysis. All authors read and approved the final draft of the paper.</p> <h3 class="c-article__sub-heading" id="FPar2">Competing interests</h3> <p>The authors declare that they have no competing interests.</p> </div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria</p><p class="c-article-author-affiliation__authors-list">Akintunde Sowunmi & Kazeem Akano</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Institute for Medical Research and Training, University of Ibadan, Ibadan, Nigeria</p><p class="c-article-author-affiliation__authors-list">Akintunde Sowunmi</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Department of Paediatrics, University of Ibadan, Ibadan, Nigeria</p><p class="c-article-author-affiliation__authors-list">Adejumoke I. Ayede</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Malaria Elimination Programme, Federal Ministry of Health, Abuja, Nigeria</p><p class="c-article-author-affiliation__authors-list">Godwin Ntadom</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">Department of Physiology, University of Ibadan, Ibadan, Nigeria</p><p class="c-article-author-affiliation__authors-list">Elsie O. Adewoye</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">World Health Organization, Regional Office for the Western Pacific, Phnom Penh, Cambodia</p><p class="c-article-author-affiliation__authors-list">Bayo Fatunmbi</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">Department of Clinical Pharmacology, University College Hospital, Ibadan, Nigeria</p><p class="c-article-author-affiliation__authors-list">Temitope Aderoyeje</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Akintunde-Sowunmi-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Akintunde Sowunmi</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Akintunde%20Sowunmi" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Akintunde%20Sowunmi" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Akintunde%20Sowunmi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Kazeem-Akano-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Kazeem Akano</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Kazeem%20Akano" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kazeem%20Akano" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kazeem%20Akano%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Adejumoke_I_-Ayede-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Adejumoke I. Ayede</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Adejumoke%20I.%20Ayede" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Adejumoke%20I.%20Ayede" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Adejumoke%20I.%20Ayede%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Godwin-Ntadom-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Godwin Ntadom</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Godwin%20Ntadom" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Godwin%20Ntadom" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Godwin%20Ntadom%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Elsie_O_-Adewoye-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Elsie O. Adewoye</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Elsie%20O.%20Adewoye" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Elsie%20O.%20Adewoye" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Elsie%20O.%20Adewoye%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Bayo-Fatunmbi-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Bayo Fatunmbi</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Bayo%20Fatunmbi" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Bayo%20Fatunmbi" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Bayo%20Fatunmbi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Temitope-Aderoyeje-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Temitope Aderoyeje</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="https://www.biomedcentral.com/search?query=author%23Temitope%20Aderoyeje" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text">You can also search for this author in <span class="c-article-identifiers"><a class="c-article-identifiers__item" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Temitope%20Aderoyeje" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Temitope%20Aderoyeje%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding author</h3><p id="corresponding-author-list">Correspondence to <a id="corresp-c1" href="mailto:akinsowunmi@hotmail.com">Akintunde Sowunmi</a>.</p></div></div></section><section data-title="Additional file"><div class="c-article-section" id="Sec27-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec27">Additional file</h2><div class="c-article-section__content" id="Sec27-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="additional file 1:" href="https://static-content.springer.com/esm/art%3A10.1186%2Fs40249-016-0165-2/MediaObjects/40249_2016_165_MOESM1_ESM.pdf" data-supp-info-image="">Additional file 1:</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Multilingual abstracts in five official working languages of the United Nations. (PDF 403 kb)</p></div></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content"> <p> <b>Open Access</b> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<a href="http://creativecommons.org/publicdomain/zero/1.0/" rel="license">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated.</p> <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Therapeutic%20efficacy%20and%20effects%20of%20artesunate-amodiaquine%20and%20artemether-lumefantrine%20on%20malaria-associated%20anaemia%20in%20Nigerian%20children%20aged%20two%20years%20and%20under&author=Akintunde%20Sowunmi%20et%20al&contentID=10.1186%2Fs40249-016-0165-2&copyright=The%20Author%28s%29.&publication=2049-9957&publicationDate=2016-07-06&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY%20%2B%20CC0">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1186/s40249-016-0165-2" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1186/s40249-016-0165-2" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Sowunmi, A., Akano, K., Ayede, A.I. <i>et al.</i> Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under. <i>Infect Dis Poverty</i> <b>5</b>, 70 (2016). https://doi.org/10.1186/s40249-016-0165-2</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1186/s40249-016-0165-2?format=refman&flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2015-11-17">17 November 2015</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2016-06-28">28 June 2016</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2016-07-06">06 July 2016</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1186/s40249-016-0165-2</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-none" hidden=""><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info"> Provided by the Springer Nature SharedIt content-sharing initiative </p></div></div><h3 class="c-article__sub-heading">Keywords</h3><ul class="c-article-subject-list"><li class="c-article-subject-list__subject"><span><a href="/search?query=Falciparum%20malaria&facet-discipline="Medicine%20%26%20Public%20Health"" data-track="click" data-track-action="view keyword" data-track-label="link">Falciparum malaria</a></span></li><li class="c-article-subject-list__subject"><span><a href="/search?query=Malaria-related%20anaemia&facet-discipline="Medicine%20%26%20Public%20Health"" data-track="click" data-track-action="view keyword" data-track-label="link">Malaria-related anaemia</a></span></li><li class="c-article-subject-list__subject"><span><a href="/search?query=Young%20children&facet-discipline="Medicine%20%26%20Public%20Health"" data-track="click" data-track-action="view keyword" data-track-label="link">Young children</a></span></li><li class="c-article-subject-list__subject"><span><a href="/search?query=Artemisinin-based%20combination%20therapies&facet-discipline="Medicine%20%26%20Public%20Health"" data-track="click" data-track-action="view keyword" data-track-label="link">Artemisinin-based combination therapies</a></span></li><li class="c-article-subject-list__subject"><span><a href="/search?query=Nigeria&facet-discipline="Medicine%20%26%20Public%20Health"" data-track="click" data-track-action="view keyword" data-track-label="link">Nigeria</a></span></li></ul><div data-component="article-info-list"></div></div></div></div></div></section> </article> </main> <div class="c-article-extras u-text-sm u-hide-print" data-container-type="reading-companion" data-track-component="reading companion"> <aside> <div data-test="download-article-link-wrapper" class="js-context-bar-sticky-point-desktop" data-track-context="reading companion"> <div class="c-pdf-download u-clear-both"> <a href="//idpjournal.biomedcentral.com/counter/pdf/10.1186/s40249-016-0165-2.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="pdf-link" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external download> <span class="c-pdf-download__text">Download PDF</span> <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg> </a> </div> </div> <div class="c-reading-companion"> <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky"> <div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections"> <div class="js-ad u-lazy-ad-wrapper u-mt-16 u-hide" data-component-mpu> <aside class="adsbox c-ad c-ad--300x250 u-mt-16" data-component-mpu> <div class="c-ad__inner"> <p class="c-ad__label">Advertisement</p> <div id="div-gpt-ad-MPU1" data-ad-type="MPU1" data-test="MPU1-ad" data-pa11y-ignore data-gpt data-gpt-unitpath="/270604982/bmc/idpjournal/articles" data-gpt-sizes="300x250" data-gpt-targeting="pos=MPU1;doi=10.1186/s40249-016-0165-2;type=article;kwrd=Falciparum malaria,Malaria-related anaemia,Young children,Artemisinin-based combination therapies,Nigeria;pmc=H33096,H61006,H27002;" > <noscript> <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/270604982/bmc/idpjournal/articles&sz=300x250&pos=MPU1&doi=10.1186/s40249-016-0165-2&type=article&kwrd=Falciparum malaria,Malaria-related anaemia,Young children,Artemisinin-based combination therapies,Nigeria&pmc=H33096,H61006,H27002&"> <img data-test="gpt-advert-fallback-img" src="//pubads.g.doubleclick.net/gampad/ad?iu=/270604982/bmc/idpjournal/articles&sz=300x250&pos=MPU1&doi=10.1186/s40249-016-0165-2&type=article&kwrd=Falciparum malaria,Malaria-related anaemia,Young children,Artemisinin-based combination therapies,Nigeria&pmc=H33096,H61006,H27002&" alt="Advertisement" width="300" height="250"> </a> </noscript> </div> </div> </aside> </div> </div> <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures"></div> <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references"></div> </div> </div> </aside> </div> </div> <div class="c-journal-footer"> <div class="c-journal-footer__inner"> <div class="c-journal-footer__summary"> <h4 class="c-journal-title c-journal-title--footer"> <span class="c-journal-title__text">Infectious Diseases of Poverty</span> </h4> <p class="c-journal-footer__issn">ISSN: 2049-9957</p> </div> <div class="c-journal-footer__contact"> <h4 class="c-journal-footer__contact-title ">Contact us</h4> <ul class="c-journal-footer__contact-list"> <li class="c-journal-footer__contact-item">Submission enquiries: <a href="https://www.editorialmanager.com/idop/" target="_blank">Access here and click Contact Us</a></li> <li class="c-journal-footer__contact-item">General enquiries: <a href="mailto:journalsubmissions@springernature.com">journalsubmissions@springernature.com</a></li> </ul> </div> </div> </div> <img rel="nofollow" class='tracker' style='display:none' src='/track/article/10.1186/s40249-016-0165-2' alt=""/> <footer> <div class="c-publisher-footer u-color-inherit" data-test="publisher-footer"> <div class="u-container"> <div class="u-display-flex u-flex-wrap u-justify-content-space-between" data-test="publisher-footer-menu"> <div class="u-display-flex"> <ul class="c-list-group c-list-group--sm u-mr-24 u-mb-16"> <li class="c-list-group__item"> <a class="u-gray-link" href="https://blogs.biomedcentral.com/">Read more on our blogs</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="//www.biomedcentral.com/login">Receive BMC newsletters</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="//www.biomedcentral.com/account">Manage article alerts</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="https://authorservices.springernature.com/go/sn/?utm_source=Website&utm_medium=BMC&utm_campaign=SNAS+Referrals+2022&utm_id=ref2022">Language editing for authors</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="https://authorservices.springernature.com/go/sn/?utm_source=Website&utm_medium=BMC&utm_campaign=SNAS+Referrals+2022&utm_id=ref2022">Scientific editing for authors</a> </li> </ul> <ul class="c-list-group c-list-group--sm u-mr-24 u-mb-16"> <li class="c-list-group__item"> <a class="u-gray-link" href="//www.biomedcentral.com/about/policies">Policies</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="//www.biomedcentral.com/accessibility">Accessibility</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="//www.biomedcentral.com/about/press-centre">Press center</a> </li> </ul> <ul class="c-list-group c-list-group--sm u-mr-24 u-mb-16"> <li class="c-list-group__item"> <a class="u-gray-link" href="https://support.biomedcentral.com/support/home">Support and Contact</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="https://biomedcentral.typeform.com/to/VLXboo">Leave feedback</a> </li> <li class="c-list-group__item"> <a class="u-gray-link" href="//www.biomedcentral.com/about/jobs">Careers</a> </li> </ul> </div> <div class="u-mb-24"> <h3 id="social-menu" class="u-text-sm u-reset-margin u-text-normal">Follow BMC</h3> <ul class="u-display-flex u-list-reset" data-test="footer-social-links"> <li class="u-mt-8 u-mr-8"> <a href="https://twitter.com/biomedcentral" data-track="click" data-track-category="Social" data-track-action="Clicked BMC Twitter" class="u-gray-link"> <span class="u-visually-hidden">BMC Twitter page</span> <svg class="u-icon u-text-lg" width="24" height="24" aria-hidden="true" focusable="false"> <use xlink:href="#icon-twitter-bordered"></use> </svg> </a> </li> <li class="u-mt-8 u-mr-8"> <a href="https://www.facebook.com/BioMedCentral" data-track="click" data-track-category="Social" data-track-action="Clicked BMC Facebook" class="u-gray-link"> <span class="u-visually-hidden">BMC Facebook page</span> <svg class="u-icon u-text-lg" width="24" height="24" aria-hidden="true" focusable="false"> <use xlink:href="#icon-facebook-bordered"></use> </svg> </a> </li> <li class="u-mt-8 u-mr-8"> <a href="http://www.weibo.com/biomedcentral" data-track="click" data-track-category="Social" data-track-action="Clicked BMC Weibo" class="u-gray-link"> <span class="u-visually-hidden">BMC Weibo page</span> <svg class="u-icon u-text-lg" width="24" height="24" aria-hidden="true" focusable="false"> <use xlink:href="#icon-weibo-bordered"></use> </svg> </a> </li> </ul> </div> </div> <p class="u-reset-margin"> By using this website, you agree to our <a class="u-gray-link" href="//www.biomedcentral.com/terms-and-conditions">Terms and Conditions</a>, <a class="u-gray-link" href="https://www.springernature.com/ccpa">Your US state privacy rights</a>, <a class="u-gray-link" href="//www.biomedcentral.com/privacy-statement">Privacy statement</a> and <a class="u-gray-link" href="//www.biomedcentral.com/cookies" data-test="cookie-link">Cookies</a> policy. <a class="u-gray-link" data-cc-action="preferences" href="javascript:void(0);">Your privacy choices/Manage cookies</a> we use in the preference centre. </p> </div> </div> <div class="c-corporate-footer"> <div class="u-container"> <img src=/static/images/logo-springernature-acb40b85fb.svg class="c-corporate-footer__logo" alt="Springer Nature" itemprop="logo" role="img"> <p class="c-corporate-footer__legal" data-test="copyright"> © 2024 BioMed Central Ltd unless otherwise stated. Part of <a class="c-corporate-footer__link" href="https://www.springernature.com" itemscope itemtype="http://schema.org/Organization" itemid="#parentOrganization">Springer Nature</a>. </p> </div> </div> </footer> </div> <div class="u-visually-hidden" aria-hidden="true"> <?xml version="1.0" encoding="UTF-8"?><!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"/></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"/></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"/></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"/></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"/></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"/></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"/></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"/></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"/></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"/></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"/></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"/></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"/></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"/></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"/></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"/></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"/></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"/></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"/></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"/></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"/></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"/></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"/></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"/></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"/></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"/></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"/></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"/></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"/></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"/></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"/></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"/></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"/></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"/></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"/></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"/></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"/></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"/></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"/></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"/></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"/></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"/></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"/></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"/></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"/><clipPath id="b"><use xlink:href="#a" style="overflow:visible"/></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"/><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"/></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"/></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"/></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"/></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"/></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"/></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"/></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"/></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"/></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"/></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"/></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"/></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"/></symbol></svg> </div> </body> </html>